Accelerated radiotherapy with carbogen and nicotinamide for carcinomas of the head and neck: a study on feasibility, toxicity and tumor response by Kaanders, J.H.A.M.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/146669
 
 
 
Please be advised that this information was generated on 2018-07-07 and may be subject to
change.
ACCELERATED RADIOTHERAPY WITH 
CARBOGEN AND NICOTINAMIDE 
FOR CARCINOMAS OF THE HEAD AND NECK 
A study on feasibility, toxicity and tumor response 
-
ν 
fr J" S 
1
 ^Jt^· 
•Saíffá 
Л-Жйк 
щ 
Шш ЯЛ^ШШ 
··. •• •-,-: • ,-Ііт- Ci 
хэ™к»ч 
^-Jf ' '"•^. τ" * 
•Ля W \ ¿ 
"'íáER 
зд» 
1?#>л 
'"•-¿'•'ι ' Д 
• \ т. ¡г-•*-
( t í • " * * » ¡ 
SÄ·*', -
ίΤϊ 
Hans Kaanders 

ACCELERATED RADIOTHERAPY WITH 
CARBOGEN AND NICOTINAMIDE FOR 
CARCINOMAS OF THE HEAD AND NECK 
A STUDY ON 
FEASIBILITY, TOXICITY AND TUMOR RESPONSE 
Cover: Computerized microscopic image of a human larynx carcinoma 
showing vascular structures (red), blood perfusion (blue), 
proliferating cells (yellow) and hypoxic regions (green). 
ISBN 90-901228-1 
ACCELERATED RADIOTHERAPY WITH 
CARBOGEN AND NICOTINAMIDE FOR 
CARCINOMAS OF THE HEAD AND NECK 
A STUDY ON 
FEASIBILITY, TOXICITY AND TUMOR RESPONSE 
Een wetenschappelijke proeve op het gebied van de 
Medische Wetenschappen 
PROEFSCHRIFT 
ter verkrijging van de graad van doctor 
aan de Katholieke Universiteit Nijmegen, 
volgens besluit van het College van Decanen 
in het openbaar te verdedigen op 
woensdag 9 december 1998 
des namiddags om 1.30 uur precies 
door 
Johannes Hendrikus Antonius Maria Kaanders 
geboren op 10 mei 1959 te Vught 
Promotores: Prof. dr. A.J. van der Kogel 
Prof. dr. W.A.J, van Daal 
Manuscriptcommissie: Prof. dr. P. van den Broek 
Prof. dr. J.W.H. Leer 
Prof. dr. Ρ H.M. de Mulder 
Publication of this thesis was financially supported by: 
Glaxo-Wellcome B.V , Janssen-Cilag B.V. and Schering-Plough B.V. 
CONTENTS 
Page 
Chapter 1 Introduction and outline of the thesis 
Chapter 2 Accelerated fractionation radiotherapy for laryngeal 19 
cancer, acute and late toxicity 
Int J Radiât Oncol Biol Phys 24 497-503, 1992 
Chapter 3 Altered fractionation limited by mucosal reactions7 37 
Radiother Oncol, accepted 
Chapter 4 A convenient and reliable method for carbogen breathing 67 
in man 
Radiother Oncol 29 341-343, 1993 
Chapter 5 Radiotherapy with carbogen breathing and nicotinamide 75 
in head and neck cancer feasibility and toxicity 
Radiother Oncol 37 190-198, 1995 
Chapter 6 Administration of nicotinamide during a five- to seven- 93 
week course of radiotherapy pharmacokinetics, 
tolerance, and compliance 
Radiother Oncol 43 67-73, 1997 
Chapter 7 Accelerated radiotherapy with carbogen and nicotinamide 111 
(ARCON) for laryngeal cancer 
Radiother Oncol 48 115-122, 1998 
Chapter 8 Summary / Samenvatting 131 
Dankwoord / Acknowledgements 139 
Curuculum Vitae 141 
List of Publications 143 

CHAPTER I 
INTRODUCTION AND OUTLINE OF THE THESIS 
Chapter 1 
Introduction 
Radiotherapy is a cornerstone of cancer treatment, both for cure and for palliation In 
the curative setting radiotherapy is attractive because of its potential for organ preservation 
This is particularly evident with the treatment of head and neck cancer, the typical example 
being early laryngeal carcinomas where cure rates of 66-93% can be obtained with 
radiotherapy alone while preserving natural speech [1] Control rates drop however for the 
more advanced stages and still often for these patients surgery is preferred Already for 
many decades the challenge for radiation oncologists has been to increase the effectiveness 
of their treatment to apply it successfully also for more advanced local disease Efforts have 
typically been focussed on three major radiation resistance mechanisms intrinsic 
radioresistant, hypoxia, and tumor cell repopulation 
Factors determining radiation response - intrinsic radiosensitivity 
Among the first observations by the early pioneers of radiotherapy was that the 
radiosensitivity of tumors varies with histologic type A categorization into three groups was 
proposed by Paterson [38] He classified embryonic tumors and reticuloses (malignant 
lymphomas nowadays) as "radiosensitive", squamous cell carcinomas and adenocarcinomas 
as of intermediate radiosensitivity", and sarcomas and melanomas as "radioresistant" 
Work in the early eighties showed that there is a correlation between the radiosensitivity of 
human tumor cell lines measured by clonogenic cell survival assay and the clinical 
responsiveness of the tumors from which the cells were derived [9, 13] The logical 
approach to improve the cure rate of radioresistant tumors is to increase the dose This 
requires sparing of normal tissues to limit side-effects Methods aimed to reduce the volume 
of normal tissue irradiated include brachytherapy and, more recently, conformai 
radiotherapy Shortly after the discovery of radium by Mane Curie and Becquerel in 1898, 
brachytherapy was already applied to the treatment of malignant tumors and is now routinely 
used for various tumor sites Computed tomography (CT) and advanced computers 
allowing three-dimensional radiation treatment planning facilitate the delivery of external 
beam radiotherapy to selected (conformed) target volumes while sparing adjacent normal 
tissues Currently dose-escalation studies with conformai radiotherapy are ongoing for 
prostate and bronchus carcinoma [18, 39] 
Another, biology based, method is hyperfractionation which is the application of a 
larger numbei of smaller dose fractions to deliver a higher total dose relative to conventional 
fractionation The îationale for this method is that late responding normal tissues have a 
greater fractionation sensitivity than acutely responding tissues including tumors The goal 
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is to improve the tumor control rate without increasing the incidence or severity of late 
sequelae. Randomized clinical trials indicate improved tumor control rates in head and neck 
cancer and bladder cancer [12, 23]. There is however some debate as to whether there is 
indeed an improvement of the therapeutic ratio because some studies also report a 
corresponding increase of late sequelae [3,44]. 
Factors determining radiation response - tumor proliferation kinetics 
During the last two decades, cellular repopulation has been recognized as an important 
cause for radiation treatment failure in various cancers, particularly squamous cell 
carcinomas [26, 28, 33, 45, 50]. Analysis of response of human tumors to fractionation 
schedules with varying overall times has shown that one week of prolongation can result in 
a 3-25% loss of local control [15]. Trott et al. attributed this to a shut down of the 
differentiation pathway and recruitment of cells into the proliferating compartment as a 
response to the radiation injury in the tumor tissue [47]. An alternative, or possibly 
coexistent, mechanism might be a reduction in the extent of natural cell loss, rather than an 
altered rate of cell production [14]. Fowler hypothesized that natural cell loss decreases 
during fractionated irradiation because of improved oxygen and nutritional supply as a 
consequence of shrinkage of the tumor cords surrounding blood vessels. Thus the effective 
tumor volume doubling time can shorten from values of around 3 months before therapy to 
potential doubling times of 3-6 days during a treatment course. Irrespective of the exact 
underlying mechanisms, there can be no doubt that with more time allowed for clonogenic 
repopulation, the chances of definitive tumor control will decrease. The importance of 
treatment duration is strongly supported by studies in experimental tumors [10, 25,42]. 
A method to shorten the overall treatment time is by delivering multiple fractions per 
day during the whole or a part of the treatment. This is called accelerated radiotherapy. 
There is now evidence from randomized clinical studies that patients with head and neck and 
bronchus carcinomas benefit from this strategy to counteract repopulation of tumor 
clonogens [2, 11, 22, 36, 43]. However, it is also becoming clear from these studies that 
certain categories of patients profit more from this approach than others. There is now a 
need to find tumor characteristics that allow identification of these patients. 
Factors determining radiation response - tumor oxygenation 
Oxygen strongly influences the biological effects of ionizing radiation. The importance 
of the "oxygen effect" to radiotherapy was recognized by Mottram [29] and later worked out 
in greater detail for mammalian tissues by Gray et al. [17]. Typically, hypoxic cells are three 
times more radioresistant than well oxygenated cells, at least at doses of 3 Gy and higher. 
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There is evidence that at lower (but clinically relevant) doses this enhancement of radiation 
damage by oxygen is somewhat less and in the order of a factor of 2 5 [37] Thomlinson 
and Gray described the classical "diffusion-limited" hypoxia model with hypoxic tumor cells 
located at a relatively constant distance from blood vessels, the diffusion distance of oxygen 
in tissue [46] This is now also called "chronic" hypoxia Later it was postulated that tumor 
hypoxia could also result from local and temporary fluctuations in tumor blood perfusion, 
so called "acute" or "transient" hypoxia [4] 
Hypoxia appears to be present in the majority of rodent solid tumors and in xenografted 
human tumors [30, 40,48] Estimates of hypoxic fractions range from below 1 % to as high 
as 95% and depend on the methods used for measuring hypoxia, tumor size, transplantation 
site, and characteristics of the host There is also substantial evidence for hypoxia in human 
tumors in situ [7] However, the oxygenation status cannot be reliably predicted from 
histology or tumor volume and thus needs to be measured in individual cases There are 
indications that tumor oxygenation predicts the prognosis of patients receiving radiotherapy 
for carcinomas of the uterine cervix and the head and neck and for soft tissue sarcomas [16, 
21, 31, 32] 
A number of strategies to overcome hypoxic cell radioresistant have been tested in the 
clinic These include the use of normobanc or hyperbaric high oxygen-content gasses, 
vasoactive agents that increase blood flow, blood transfusions or artificial oxygen-carrying 
blood substances (perfluorocarbons), stimulation of hemoglobin production by 
erythropoietin, and hypoxic cell radiosensitizers Other methods such as hyperthermia and 
bioreductive drugs preferentially kill hypoxic cells and can be used in combination with 
radiotherapy A meta-analysis of 72 randomized clinical trials of radiotherapy either alone or 
combined with a treatment to modify tumor hypoxia showed improvement of loco-regional 
control and survival following manipulation of tumor hypoxia [34] When analyzed 
according to site, this improvement was dominated by the head and neck tumors Three 
randomized studies, two in head and neck carcinoma and one in carcinoma of the uterine 
cervix, demonstrated improved loco-regional control and survival after radiotherapy in 
hyperbaric oxygen relative to treatment in air [19, 20, 49] A recent randomized study 
showed increased tumor control and survival advantage in patients with supraglottic and 
pharynx carcinomas with the hypoxic radiosensitizer nimorazole [35] However, as with 
alteied fractionation regimens, there aie indications from these clinical trials that certain 
subgroups of patients will benefit from hypoxia modification more than others 
- 10-
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Outline of the thesis 
For each of the above discussed radioresistant mechanisms there are examples of 
clinical studies proving that counteracting these mechanisms can be beneficial for treatment 
outcome The gain, expressed in terms of loco-regional tumor control, is in the range of 5 to 
23% [2, 8, 11, 19, 20, 22, 23, 35, 36, 43, 49] These are important improvements but, 
also with these new approaches, still a significant proportion of the cases remains 
uncontrolled Often in the analyses certain subgroups of patients emerged that did 
particularly well on the investigational treatment Furthermore, although one of the 
resistance mechanisms may dominate in a certain tumor, there is no reason to assume that 
the other mechanisms will not influence treatment outcome 
Future work should therefore concentrate on the following objectives 
1 ) Identification of tumors or classes of tumors that are most effectively 
treated by either of the new radiotherapy approaches 
2) Combination of treatment modifications that counteract different 
radioresistance mechanisms 
The aim of this work was to prepare a strategy which combines methods for hypoxic 
modification with accelerated radiotherapy for application in the clinic The feasibility and 
toxicity of this treatment were investigated in head and neck cancer patients Subsequently 
its effectiveness in patients with advanced laryngeal cancer was assessed 
A schedule foi accelerated fractionated radiotherapy was designed employing moderate 
reduction of overall treatment time with unchanged total dose and dose per fraction relative 
to conventional treatment This was accomplished by delivering two fractions per day 
duung the last part of the treatment A secondary but not unimportant advantage of this 
schedule is that it does not increase workload on the treatment machines because the number 
of fractions remains unchanged In chapter 2 the toxicity of this schedule was compared to 
that of conventional treatment in patients with laryngeal cancer 
Aftei this study it was concluded that the schedule is feasible but that further shortening 
of oveidll tieatment time without reduction of total dose may lead to unacceptable acute and, 
possibly, also late mucosal toxicity Chapter 3 reviews the experimental and clinical data 
on radiation mucositis available in the literature in order to assess whether indeed the upper 
aerodigestive tract mucosa is limiting to treatment intensification by altered fractionation 
The clinical data indicate that, relative to a conventional treatment of 7 weeks, the maximum 
achievable gain in tieatment time is 2 weeks with the mucosa being the limiting tissue Any 
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further acceleration requires a reduction of dose which can be disadvantageous, in particular 
for tumors with lower intrinsic radiosensitivity 
One strategy to further improve the treatment outcome can be to combine accelerated 
radiotherapy with hypoxic modifiers Studies in rodent tumors demonstrated significant 
sensitization when Accelerated fractionated Radiotherapy was administered together with a 
combination of CarbOgen and Nicotinamide ("ARCON") [41, 42] Carbogen is a gas 
mixture containing 95% oxygen and 5% carbon dioxide and breathing of this mixture causes 
a rise of the oxygen partial pressure in the blood and tissues With the use of an 
immunohistochemically detectable hypoxic marker it was demonstrated that carbogen very 
effectively reduced diffusion-limited hypoxia in xenografted human laryngeal carcinomas 
[5] This effect of carbogen was also shown in patients with head and neck tumors by direct 
measurements with oxygen electrodes in metastatic lymph nodes [27] Nicotinamide, the 
amide derivative of vitamin B3, can reduce the intermittent closure of blood vessels in 
experimental rodent tumors and consequently decrease transient hypoxia [6, 24] With 
carbogen an enhancement ratio of 1 5 was obtained in mouse tumors with radiation doses 
close to those used clinically This means that, to obtain the same tumor control rate as with 
radiotherapy alone, a 1 5 times lower radiation dose was needed when radiotherapy was 
given in combination with carbogen Addition of nicotinamide gave further 
radiosensitization to an enhancement ratio of 1 7 Finally, when also accelerated 
fractionation was incorporated, the complete ARCON treatment resulted in an enhancement 
ratio of 1 9 indicating an almost twofold increase of the effectiveness of this treatment 
relative to conventional radiotherapy alone [42] These promising results justified testing of 
this treatment in the clinic 
For this purpose patients with squamous cell carcinomas of the head and neck were 
selected because there was already evidence that this category can benefit both from 
acceleration and from hypoxic modification Additional arguments were that the loco-
regional control rate for the more advanced cases is not yet satisfactory and that organ 
preservation in the head and neck region is of great value Finally, this region is easily 
accessible for assessment of normal tissue reactions and tumor response and thus is 
attractive as a "test site" for new treatments 
For administration of carbogen a dependable and convenient breathing system was 
required which could be combined with techniques for immobilization of the patient A 
method based on professional diving equipment was developed and is presented in 
chapter 4 
After experience was gained with a schedule for accelerated fractionation (chapter 2), 
carbogen and nicotinamide were added to this treatment in consecutive steps Chapter 5 
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reports on the feasibility and toxicity of these components. It was concluded that 
radiotherapy combined with carbogen and nicotinamide is a safe treatment with manageable 
side-effects. Based on experience with nicotinamide in other diseases it was suggested that 
this is a relatively non-toxic agent with a low incidence of side-effects even at the high dose 
levels required to obtain the sensitizing effect. However, gastrointestinal side-effects were 
observed frequently in the head and neck patients and severe renal toxicity was observed in 
a few. Recommendations to improve the safe use of nicotinamide were formulated and the 
pharmacokinetics, tolerance, and compliance to the drug were further investigated which is 
described in chapter 6. 
Chapter 7 presents the outcome of the new treatment in 62 patients with stage III-IV 
squamous cell carcinoma of the larynx. The literature on radiotherapy for advanced 
laryngeal cancer is briefly reviewed and results are compared with the outcome of the 
current study. 
Chapter 8 provides a summary of this work. 
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Chapter 2 
Abstract 
The acute toxicity of an accelerated radiotherapy scheme was compared with a 
conventional schedule Eighteen patients with squamous cell carcinoma of the larynx were 
treated with accelerated fractionation radiotherapy An average reduction of the overall 
treatment time of 11 days was accomplished by giving two fractions a day during the last 
part of the treatment The total dose and fraction dose were left unchanged The acute 
reactions of skin and mucosa in these patients were compared with those in 40 patients 
treated with a conventional fractionation scheme, that is, 2 Gy per fraction, five fractions per 
week, to a total dose of 64-70 Gy 
The acute reactions were maximal between 5 and 7 weeks after the start of treatment 
Complete healing occurred within 3 months in all patients The mucosal reactions and, as a 
consequence, dysphagia were clearly increased in those patients treated with accelerated 
fractionation For confluent mucositis an ED50 of 66 Gy was calculated compared to 69 Gy 
for conventional fractionation To a lesser degree, skin toxicity was also enhanced in the 
patients treated with the accelerated schedule 
Severe edema of the laryngeal mucosa occurred only in patients treated to a total dose of 
68 or 70 Gy and was somewhat more frequent with accelerated fractionation (4/10) than 
with conventional fractionation (4/24) One patient in the accelerated fractionation group 
underwent laryngectomy for persistent edema and laryngeal necrosis No severe late skin 
reactions were observed 
It can be concluded that the fractionation schedule tested in this study is feasible 
Further shortening of the overall treatment time without reduction of the total dose will likely 
lead to unacceptable acute and, possibly, also late toxicity 
- 2 0 -
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Introduction 
When treating laryngeal cancer by radiotherapy there is a need to optimize the irradiated 
volume, total dose, dose per fraction and overall treatment time Whether the conventional 
system of fractionation (1 e 60-70 Gy in 2 Gy fractions, five times a week) is the optimal 
way of delivering radiotherapy in all circumstances is highly debatable at this moment [16, 
19, 21] 
Accelerated fractionation, as an alternative to conventional fractionation, is defined as 
shortening the overall treatment time without changing total dose nor fraction size, by giving 
two or three doses daily The rationale for attempting to improve the therapeutic ratio by 
accelerated fractionation is based primarily on the premise that shortening the overall 
treatment time reduces the opportunity for proliferation of tumor cells during treatment and, 
thereby, increases the probability of tumor control for a given dose level The acute normal 
tissue reactions will be exacerbated for the same reason, but assuming that repair is complete 
between fractions, one expects little or no change in the response of the slowly cycling 
target cells of late reacting tissues [4] 
Withers et al analyzed the results of radiotherapy in head and neck cancer [22] Using 
the data of 59 clinical studies from the literature, they observed that after a lag period in the 
order of 4 weeks a dose increment of about 0 6 Gy for each additional day of tieatment is 
needed for a constant level of tumor control They suggested that a net increased 
repopulation of tumor clonogens becomes effective after this lag period The same 
conclusions have been drawn from a retrospective clinical study [11] Several other clinical 
studies indicate that accelerated fractionation may be a promising treatment modality foi head 
and neck cancer [1,8, 15, 20] 
These considerations prompted us to conduct a study on accelerated fractionation, 
concomitant boost type In contrast to other clinical studies where the total dose or dose per 
fraction were lowered to accomplish sufficient reduction of treatment time, we only 
shortened the overall treatment time without changes in other parameters We elected to 
study a well defined, homogeneous population, that is, patients with laryngeal cancer Oui 
first goal was to evaluate and document the toxicity of the accelerated schedule in 
comparison with conventional daily fiactionation which forms the basis of this repoit 
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Methods and materials 
Only patients with histologically proven squamous cell carcinoma of the larynx were 
eligible for the study The tumors were staged according to the "TNM classification for 
malignant tumours" as defined by the UICC [7] Patients with Tj, T2 or T3 tumors, with or 
without neck node metastases but without distant metastases were included Informed 
consent was obtained after the nature of the procedure was explained All patients starting 
treatment between December 1st, 1987 and March 31 s t , 1988 were assigned to receive 
accelerated fractionation radiotherapy (AF) These patients were compared to consecutive 
patients treated by conventional fractionation radiotherapy (CF) between April 1st, 1988 and 
February 28 th, 1989 The same criteria for tumor site, histology, and TNM-stage were 
used 
All patients weie treated on a linear accelerator using 4 MV photons The larynx and 
subdigastnc and midjugular lymph nodes were irradiated through lateral parallel opposed 
portals except for T1N0 disease where only the larynx was included In patients presenting 
with nodal metastases an anterior appositional field was added to treat the lower neck nodes 
The boost dose to the primary tumor and involved lymph nodes was given through lateral 
photon fields 
In our institution, conventional fractionation consists of a dose of 44 Gy, given to the 
initial target volume as described above This is followed by a boost to a total dose of 64-
70 Gy, depending on T-stage (64 Gy for T\ tumors, 68 Gy for T2 and 70 Gy for T3) The 
dose per fraction is 2 Gy and five fractions per week are given Overall treatment time is 44-
50 days For those patients receiving accelerated fractionation radiotherapy, total dose and 
dose per fraction were the same as for those receiving conventional treatment The total 
treatment time, however, was reduced to 36-39 days This was achieved by giving two 
fractions a day in the last part of the treatment period (Fig 1), using a minimal interval of 
6 h between fiactions Dose specification was according to the recommendations of the 
ICRU in Report 29 [6] Computer planning was used for optimization of dose distribution 
The patients were examined by two radiation oncologists at least once a week during 
and after treatment until the acute side-effects had subsided Skin and mucosal reactions as 
well as dysphagia were scored on a five-point scale (Table 1) The tumor response was 
assessed Subsequently the patients returned for follow-up every 2 months during the first 
year and every 3 months during the second year Late effects of irradiation were considered 
severe if there was ulceration of skin 01 mucous membranes, seveie edema of the laryngeal 
mucosa or chondritis and/or necrosis of cartilage These items have been selected from the 
"system for recording of radiation-morbidity" as proposed by Lartigeau et al [10] 
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Table 1. Scores for acute radiation reactions. 
Skin 
Mucosa 
Dysphagia 
Acute reactions 
normal 
slight redness 
severe redness 
dry desquamation 
moist desquamation 
normal 
slight redness 
severe redness 
spotted mucositis 
confluent mucositis 
normal 
complaints, no medication 
medication needed 
liquid feeding 
tube feeding 
Score 
0 
1 
2 
3 
4 
0 
1 
2 
3 
4 
0 
1 
2 
3 
4 
Conventional fractionation: total dose 70 Gy, dose per fraction 2 Gy, overall time 
47 days (vertical bars below horizontal line indicate boost). 
Accelerated fractionation: total dose 70 Gy, dose per fraction 2 Gy, overall time 
37 days (vertical bars below horizontal line indicate boost) 
Fig. 1. Diagrammatic representation of the fractionation schemes used in the present 
study 
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Mean values of the weekly toxicity scores were calculated for each treatment group 
Fisher's exact test was used to test the statistical significance of differences between 
treatment groups Spearman's correlation coefficient was calculated to test relationships 
between early and late effects 
For calculation of isoeffective doses, dose-response curves were constructed by 
plotting the proportion of patients with a certain toxicity score versus radiation dose Where 
possible, ED50 values and confidence limits were calculated by probit analysis and 
compared by the chi-square test 
Results 
Eighteen patients weie treated with accelerated fractionation Table 2 shows TNM-stage 
and total dose given The mean treatment time was 36 days for patients treated to 64 Gy and 
38 days for patients treated to 68 or 70 Gy These 18 patients were compared to 40 controls 
who received conventional radiotherapy The mean treatment time for this latter group of 
patients was 47 days for those receiving 64 Gy and 49 days for those treated to 68 or 
70 Gy The difference in overall treatment time between the AF-group and the CF-group 
was thus 11 days All patients completed the planned treatment without interruption 
Follow-up was 30-40 months for the CF-group and 39-42 months for the AF-group 
Table 2. Numbers of patients by stage, total dose, and fractionation schedule applied 
CF-group AF-group 
T|SNoMo 
T1N0M0 
T2N0M0 
T3N0M0 
64 Gy 
68 Gy 
70 Gy 
2 
14 
18 
6 
16 
18 
6 
40 
T1N0M0 
T2N0M0 
T2N2M0 
T3N0M0 
64 Gy 
68 Gy 
70 Gy 
9 
7 
1 
1 
8 
9 
1 
18 
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Acute toxicity 
Skin: The average skin reaction reached its peak between 5 and 7 weeks after the start 
of radiotherapy in both treatment groups (Fig. 2). Table 3 presents the proportion of patients 
that developed dry or moist desquamation. Moist desquamation was observed 
predominantly in those patients treated by accelerated fractionation and to a dose of 68-
70 Gy. On the average this reaction level was reached on day 45 after the start of irradiation 
and persisted for 2 weeks. The skin reactions healed completely within 3 months after start 
of treatment in all patients. 
Mucosa: The earliest mucosal reactions (redness) were observed 1 week after the start 
of treatment. As expected, reactions during the initial 4 weeks of treatment were comparable 
in both treatment groups since the first part of the irradiation schedule was identical for all 
patients. Maximal reactions usually consisted of spotted or confluent mucositis. The average 
score was highest 5 to 7 weeks after start of treatment (Fig. 3). The proportion of patients 
Table 3. Acute toxicity scores by fractionation schedule (CF = conventional fractionation, 
AF = accelerated fractionation) and total dose. 
skin > 3 
skin = 4 
mucosa > 3 
mucosa = 4 
dysphagia > 2 
skin > 3 
skin = 4 
mucosa > 3 
mucosa = 4 
dysphagia > 2 
CF 
3/16 (19%) 
0/16 (0%) 
Θ/16 (50%) 
0/16(0%) 
5/16 (31%) 
C F 
19/24 (79%) 
2/24 (8%) 
17/24 (71%) 
11/24 (46%) 
12/24 (50%) 
64 Gy 
n.s.* 
n.s.* 
ρ = 0.02* 
n.s.* 
n.s.* 
68-70 Gy 
n.s.* 
ρ =0.01* 
n.s.* 
ρ = 0.02* 
ρ <0.01* 
A F 
3/8 (38%) 
0/8 (0%) 
8/8 (100%) 
1/8 (13%) 
5/8 (63%) 
A F 
9/10 (90%) 
5/10 (50%) 
9/10(90%) 
9/10(90%) 
10/10 (100%) 
'Fisher's exact test 
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Fig. 2. Average skin score during and after treatment. Treatment starts at "week 0". 
Open symbols represent conventional fractionation, closed symbols represent 
accelerated fractionation. Vertical bars indicate standard error of the mean. 
Fig. 2A includes patients irradiated to a dose of 64 Gy. Fig. 2B includes 
patients irradiated to a dose of 68 or 70 Gy. 
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Fig. 3. Average mucosal score during and after treatment. Treatment starts at "week 0 ". 
Open symbols represent conventional fractionation, closed symbols represent 
accelerated fractionation. Vertical bars indicate standard error of the mean. 
Fig. ЗА includes patients irradiated to a dose of 64 Gy. Fig. 3B includes 
patients irradiated to a dose of 68 or 70 Gy. 
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with spotted or confluent mucositis is given in Table 3. With a total dose of 64 Gy, spotted 
mucositis developed more often in the AF-group while confluent mucositis was rare in both 
groups. In the 68-70 Gy dose groups, most patients in both groups developed spotted 
mucositis. The incidence of confluent mucositis was significantly higher in the AF-group. 
The average time at which confluent mucositis was reached was day 34 in the CF-group and 
this reaction level was maintained for an average of 26 days. In the AF-group confluent 
mucositis was reached on day 38 and persisted for 24 days. Again, complete healing 
occurred within 3 months in all cases. 
Dysphagia: The need for medication against dysphagia in the different treatment groups 
is shown in Table 3. Tube feeding and hospitalization for a period of 1 week was needed for 
one patient in the AF-group (stage T2N0, total dose 68 Gy). No patients in the CF-group 
required nutritional support of this kind. 
For the endpoints skin score > 3 and mucosa score = 4, dose response curves 
were constructed using probit analysis (Fig. 4). The ED50 for confluent mucositis was 
69 Gy in the CF-group and 66 Gy in the AF-group, which is a statistically significant 
difference (p < 0.05). Assuming that repopulation accounts for this 3 Gy difference, a mean 
recovery of 0.3 Gy per day can be derived for the laryngeal mucosa. The ED50 for skin 
reaction showed no significant difference for the two treatment modalities. 
Late toxicity 
Severe late effects were observed only in those patients treated up to a total dose of 68 
or 70 Gy either by conventional or accelerated fractionation. In the AF-group, four of 10 
patients developed severe edema of the laryngeal mucosa. In three patients it appeared 2 to 7 
months after completion of treatment and regressed spontaneously within 6 months without 
causing serious discomfort. In one of these patients there was also a small area with 
transient mucosal ulceration on the false cord. This defect healed spontaneously within 5 
months. One patient was seen with severe edema directly after completion of the course of 
irradiation which, 3 months later, was accompanied by necrosis of cartilage requiring total 
laryngectomy. No tumor was found in the specimen. After conventional fractionation 
radiotherapy, severe edema was observed in four of 24 patients. In three cases this was 
observed 3 to 5 months after completion of the treatment. Spontaneous regression occurred 
within 6 months. One patient developed severe edema after 2 years of follow-up, persisting 
at the moment this report was written. We have no evidence of recurrent tumor in this 
patient so far. 
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Fig. 4. Dose response curves for skin score > 3 (A) and mucosa score = 4 (B) 
constructed by probit analysis. Closed and open symbols represent datapoints of 
the accelerated and conventional schedules respectively. Horizontal bars 
represent 95% confidence limits. 
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Although it did not reach the level of statistical significance (Spearman's correlation 
test, ρ = 0.09), it is of interest to note that there was the indication of a correlation between 
the severity of acute mucosal reactions and laryngeal edema, irrespective of total dose 
delivered, suggesting these late effects to be "consequential" to acute effects and not of 
independent origin. All patients treated with accelerated fractionation that developed 
confluent mucositis in the acute phase also showed some degree of edema of the laryngeal 
mucosa some time in follow-up. Those patients whose peak mucositis score was 3 or less 
never developed any laryngeal edema. 
No severe late skin reactions were reported in any of the patients. 
Discussion 
To study the influence of different irradiation parameters such as total dose, dose per 
fraction and overall treatment time, one should alter only one of these parameters at a time. 
We chose to study moderate reduction of overall treatment time in order to leave total dose 
and dose per fraction unchanged. All previously reported schedules for accelerated 
fractionation in head and neck cancer reduced the total dose or dose per fraction (< 2 Gy) or 
both to accomplish sufficient reduction of overall treatment time. Mostly patients with 
advanced carcinoma of the head and neck were studied, regardless of site of origin of the 
tumor. We believe that the biological properties of tumors differ with their site of origin. 
Also side-effects of irradiation are obviously related to the site of the tumor and the area 
treated. We therefore elected to study a well defined, homogeneous population, that is, 
patients with laryngeal cancer. 
We used a concomitant boost type fractionation schedule with the acceleration of the 
treatment taking place at the end of the treatment series. With a schedule like this the acute 
reactions will be postponed to the end of the treatment period, thereby lowering the risk of 
interruption of the treatment for this reason. Available radiobiological and clinical data 
incorporated in mathematical models point towards concomitant boost schemes as being 
potentially the most successful in terms of tumor control [14, 17]. The role of proliferation 
as an important factor in tissue recovery after radiation, not only in tumors but also in 
normal tissues, is widely recognized [5]. It is therefore not surprising that we observed 
more severe acute reactions, especially mucosal reactions, with accelerated fractionation. As 
expected, there was no difference during the first 4 weeks of treatment since acceleration in 
the AF-group was not started until the fourth week. 
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Ang et al. showed that repopulation in mouse lip mucosa increases during the first 10 
days after the initial dose of radiation [2]. They calculated that, between the 7 th and 10th 
day, repopulation accounts for about 1.0 Gy of recovery per day. From our material we 
calculated a mean recovery of 0.3 Gy per day for laryngeal mucosa over the entire treatment 
period. This could indicate a higher potential for repopulation in mouse than in man as 
suggested by Dörr et al. [3]. The comparison however is hampered by different definitions 
of endpoints. Van der Schueren et al. studied mucosal and skin reactions in patients treated 
by different fractionation regimens [18]. They observed confluent mucositis in all patients 
treated up to 70 Gy by conventional fractionation radiotherapy. The average time at which 
this reaction level was reached was day 22 and it persisted for about 5 weeks. They 
suggested a threshold for confluent mucositis of approximately 20 Gy when given in 
fractions of 1.6-2 Gy which then would become apparent 9 days after delivery of this dose. 
In the present study we observed a lower incidence of confluent mucositis (42%) in patients 
treated to a comparable dose level by conventional fractionation. This reaction level was also 
reached later (day 34) which is 20 days after the point at which 20 Gy had been 
administered. We thus find a lower incidence and a slower development of confluent 
mucositis in our material. Van der Schueren et al. studied patients with advanced head and 
neck tumors and it is conceivable that treatment volumes were larger in their patients, 
including more of the oropharyngeal and oral mucosa. Possibly also the general condition of 
these patients was poor due to their large tumors. This indicates that mucosal reaction 
patterns do not only depend on dose and fractionation schedule. Factors such as irradiated 
mucosal surface, sites treated and general condition of the patient may also play an important 
role. 
A study on concomitant boost radiotherapy in nasopharyngeal and oropharyngeal 
cancer was conducted at the MD Anderson Cancer Center [1]. Initially patients were 
randomized over three different treatment-arms. The boost was either given twice a week 
during the 5 to 6 weeks of the basic treatment course (arm 1), or every day during the first 
2-2.5 weeks (arm 2) or during the last 2-2.5 weeks (arm 3). Later arms 1 and 2 were 
dropped because the tumor control rate of arm 3 appeared to be superior and it was 
logistically the most convenient schedule. Arm 3 is comparable to our fractionation scheme. 
Daily fractions of 1.8 Gy, five times a week were given for 6 weeks. The boost consisted of 
10 to 12 fractions of 1.5 Gy. Thus, total dose ranged between 69 Gy and 72 Gy given in 6 
weeks. In this treatment group 35 of 43 patients (81%) developed confluent mucositis. This 
is comparable with the incidence of confluent mucositis that we found in our study in those 
patients that were treated to a total dose of 68 or 70 Gy (9/10 or 90%). In five of 43 patients 
they observed mucositis lasting 6 weeks or longer after completion of treatment. In our 
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experience mucositis had always disappeared at this point Irradiated mucosal surface and 
site treated might bring about this difference 
In the MD Anderson study as well as in the present study, the overall treatment time 
was reduced without reduction of total dose Further shortening of treatment time, as tested 
by Lamb et al in patients with advanced head and neck cancer [9], requires adjustment of 
the total dose to prevent excessive mucosal reactions They delivered three fractions of 
1 8 Gy, 4 h apart, on 3 treatment days per week (Monday, Wednesday, Friday) to a total 
dose of 59 4 Gy delivered in 33 fractions over 24-25 days With this regimen they observed 
severe acute mucosal reactions with haemorrhagic mucositis in some patients and 52% of 
patients required hospital admission 
Peracchia et al drastically reduced the treatment time to 9-11 days and delivered a dose 
of 48-54 Gy by three times a day fractionation [13] The dose per fraction was 2 Gy with an 
interval between fractions of at least 3 h Persistent confluent mucositis occurred in all 
patients, leading to necrosis in 68% of patients On the contrary, acceptable acute toxicity 
was reported by Olmi et al using an almost identical schedule [12] 48-52 Gy were 
administered over a total time of 11-12 days, three times a day 2 Gy with a 4 h gap between 
each session By reducing dose per fraction to 1 5 Gy and increasing the interval between 
fractions to 6 h, Saunders et al managed to deliver 54 Gy in 12 consecutive days [15] 
Acute mucosal reactions were reported to be troublesome but tolerable They demonstrated 
that extremely short schedules are feasible but require adjustment not only of total dose but 
also of dose per fraction 
Severe laryngeal edema was seen somewhat more often m those patients treated by the 
accelerated scheme to a dose of 68-70 Gy four of 10 versus four of 24 in the CF-group 
This edema was transient in all but one case in which it was accompanied by necrosis of 
cartilage necessitating laryngectomy This patient continued heavy smoking and drinking 
during and after radiotherapy 
Of interest is a possible correlation between acute mucosal reactions and later onset of 
laryngeal edema Our patient numbers in this study however may be too small to confirm 
this relationship and we are currently investigating a larger group of patients If indeed 
laryngeal edema proves to be related to severe acute mucosal reactions irrespective of total 
dose and fractionation schedule, one might consider this a "consequential late effect" as 
defined by Peters et al [14] The side-effects observed by Perrachia et al in their study on 
accelerated fractionation for head and neck cancer aie a typical example of this phenomenon 
non-healing mucositis leading to necrosis after 4-5 months [13] Also Olmi et al observed a 
high incidence (24%) of severe late damage but they found no relationship between acute 
and late sequelae [12] 
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Most other investigators do not report significant increase of late toxicity after moderate 
reduction of overall treatment time [1,9, 20]. The schedule used in Mount Vernon Hospital 
resulted in late toxicity of skin and mucosa comparable to that of conventional radiotherapy 
[10]. However, they also report a trend towards more pallor and telangiectasia in patients 
where early mucosal reactions took longest to heal. Recovery of hair loss and salivary gland 
function was even better after accelerated fractionation, possibly due to the lower total dose 
that was delivered with this regimen. 
Since the availability of high energy photons, skin reactions are usually not dose 
limiting anymore. There was an increased incidence of moist desquamation in our patients 
treated by accelerated fractionation and to a total dose of 68-70 Gy. However, it is our 
experience and of others [1, 9, 18] that these reactions are relatively easy to overcome and 
have less functional impact than mucosal reactions. 
Increased acute toxicity is associated with all schedules of accelerated fractionation as is 
confirmed by this study. With moderate reduction of the overall treatment time by 11 days 
acute reactions remain tolerable although one should be aware of the potential hazard of 
consequential late damage. Further shortening of treatment time is not feasible without 
adjustment of other irradiation parameters such as total dose and dose per fraction. 
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Abstract 
The effectiveness of accelerated fractionation and hyperfractionation in cancer of the 
head and neck has been confirmed in randomized studies These new fractionation strategies 
are almost invariably accompanied by an increase of early normal tissue reactions, in 
particular mucosal reactions This paper presents a survey of the available experimental and 
clinical mucositis data and aims to assess as to what extent the upper aerodigestive tract 
mucosa is limiting to treatment intensification by altered fractionation 
The rate of dose delivery is the most important determinant for early radiation reactions 
With accelerated radiotherapy, relative to a conventional treatment of 7 weeks, the maximum 
achievable gain in treatment time is 2 weeks with the mucosa being the limiting tissue Any 
further acceleration requires a reduction of dose Manipulations with the temporal 
distribution of dose, fraction dose, and optimization of interfraction intervals can improve 
tolerance but probably do not allow significant further intensification of the existing 
accelerated schedules Dose escalation by hyperfractionation does not seem to be directly 
limited by early mucosal reactions Late reacting tissues are more likely to limit 
intensification of these schedules 
Suggestions for further improvement of treatment outcome include generation of a 
potent agent which can ameliorate radiation mucositis and so permit furthei intensification of 
radiotherapy schedules, combination of altered fractionation schedules with hypoxic 
modifiers, and tailoring of the treatment strategy based on patient and tumor characteristics 
- 3 8 -
Alte red fractionation and mucositis 
Introduction 
Altered fractionation schedules as means to improve radiation treatment outcome have 
been the subject of extensive clinical testing, especially during the last decade Now, 
randomized studies have confirmed the effectiveness of accelerated fractionation and 
hyperfractionation in some cancer sites of the head and neck area [2, 16, 20, 39, 40, 65] 
These new fractionation schedules were designed to enhance the therapeutic ratio by 
improving tumor control without increasing late toxicity Hyperfractionation exploits the 
difference in the fractionation sensitivity between rapidly and slowly renewing tissues, ι e a 
higher total dose can be given when the dose per fraction is reduced With accelerated 
fractionation the radiation dose is delivered in reduced overall treatment time by giving 
multiple fractions per day Provided that sufficient time between the fractions is allowed for 
repair of sublethal damage to approach completion, no or only marginal increase of late 
morbidity is expected But what about acute reactions9 Already in 1932 it was Coutard who, 
based on clinical observation and logic reasoning, stated "An obseivation of the facts leads 
us to admit that the radiosensitivity of cancer cells of epidermal origin is usually of the same 
degree as the radiosensitivity of the germinal cells of the epidermis" [14] In fact, this 
became his guidance for dosing individual patients Consistent with this principle and not 
surprisingly, the new fractionation strategies are almost invariably accompanied by an 
increase of early normal tissue reactions, in particular mucosal reactions 
The purpose of this paper is to review the available experimental and clinical mucositis 
data and to assess as to what extent the upper aerodigestive tract mucosa is limiting to 
treatment intensification by altered fractionation 
Assessing and reporting mucosal reactions 
Before reviewing the data from the literature it is important to emphasize some aspects 
that are essential for adequate assessment and useful reporting of mucosal reaction patterns 
First of all endpoints should be clearly defined It is not uncommon that in scientific 
papers descriptions such as "brisk" or "severe mucositis" aie used without further details 
Mere use of the term "mucositis" insufficiently describes the condition that is being looked 
at A further specification is required, e g "confluent mucositis" indicating that confluent 
pseudomembranes were observed, if possible with an indication of the relative mucosal 
surface affected The use of composite scales is discouraged These scales combine multiple 
elements of tissue reactions, sometimes both objective and subjective, into one composite 
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score. The interpretation of such scores is difficult and it complicates the understanding of 
mechanisms behind the acute tissue responses. The frequency of radiation side-effects 
should be expressed quantitatively, avoiding terms as "most", "common" or "some" which, 
unfortunately, are still often used. 
Another aspect is the difference of reaction patterns by head and neck subsite. This too 
was already described by Coutard in his paper of 1932 [14] but is still very often ignored. 
Fig. I compares the incidence of confluent mucositis in larynx and oropharynx. We treated 
patients with a conventional schedule to a dose of 68 Gy in fractions of 2 Gy over 7 weeks. 
The mucosal reactions were observed weekly during and after the treatment until healing 
was complete. Confluent mucositis was more frequently observed in the oropharynx. A 
similar observation was made by Denham et al. comparing hypopharynx and oropharynx 
[19]. It is not clear whether these differences by site persist with intensified treatments. In 
this paper we can only consider the upper aerodigestive tract mucosa in general because of a 
lack of sufficiently detailed data for subsites. 
When is mucositis to be considered as severe and when do mucosal reactions become 
limiting to further treatment intensification? Obviously, the highest grade on the objective 
scoring scale is an indicator but definitely not the only one and probably also not the best 
proportion 
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Fig. 1. Proportion of patients with confluent mucositis during and after conventional 
radiotherapy comparing larynx and oropharynx. 
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one. Some scales have "confluent mucositis" as the highest grade but others include 
"ulceration" or "necrosis" as an even higher level of damage. The latter however is rare as 
an early event. Confluent mucositis is observed frequently, also with conventional treatment 
(Fig. 1). Acceleration of treatment produces confluent mucositis in the great majority of 
patients. Despite this high incidence of confluent mucositis with altered fractionation, most 
schedules are considered as acceptable with regard to acute toxicity. This is because the 
mucosa generally heals within a reasonable period of time and without significant 
consequential late effects. The duration and completeness of the healing process in fact 
determine whether the limits of tolerance are being reached. Confluent mucositis represents 
a certain level of cellular depletion of the mucosal lining. It was suggested by van der 
Schueren et al. that, in the human oral mucosa, a threshold dose of 20 Gy is needed to cause 
confluent mucositis [81]. In their clinical experiments, further increase of the radiation dose 
directly influenced the duration of mucositis. The time that is required for healing very likely 
reflects the degree of mucosal stem cell kill. If there is (nearly) complete depletion of stem 
cells in a certain area, regeneration depends on proliferation and migration from the edges of 
the lesion. The larger the affected area the more time will be needed for complete recovery 
and the higher the risk of persistent, consequential damage. Fig. 2 illustrates how increased 
levels of damage are expressed as prolonged duration of mucosal reactions. The figure 
presents data from a toxicity study of accelerated fractionation combined with carbogen and 
nicotinamide as modifiers of hypoxia in patients with larynx- and hypopharynx carcinomas 
[46, 47]. A total dose of 64-68 Gy was delivered in 2 Gy fractions over a 5-5.5 week 
period. The overall treatment time was moderately reduced by delivering two fractions per 
day during the last one and a half week of the radiation course. The interval between 
fractions was at least 6 h and the dose per fraction 2 Gy. Carbogen and nicotinamide were 
added in consecutive phases of the study. With acceleration alone 90% of patients developed 
confluent mucositis. Further enhancement by carbogen and nicotinamide was reflected by 
prolonged healing times. 
Other indicators of the severity of mucosal reactions can be dysphagia, use of 
analgetics, weight loss, tube feeding and hospitalization. To a large degree these are 
subjective parameters and dependent on local and individual treatment policies. For 
example, in some institutes there is a tendency to perform a percutaneous gastrostomy 
earlier in the treatment to prevent excessive weight loss. Also, when multiple fractions per 
day are given, patients are often hospitalized but it is not always reported whether this was 
because of severe side-effects or just because of logistic reasons. These parameters 
obviously are important indicators of the patients' well being. However, they do not very 
accurately reflect the biological effects of radiation. 
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Fig. 2. Proportion of patients with confluent mucositis during and after radiotherapy 
comparing conventional radiotherapy (conv), accelerated radiotherapy (ace), 
accelerated radiotherapy with carbogen (acc+carb), and accelerated radiotherapy 
with carbogen and nicotinamide (acc+carb+nic). 
Even when only objective endpoints are used it is difficult to compare studies because 
of the differences in patient selection and tumor characteristics and inter-observer variations. 
For example, the concomitant boost schedule developed at the MD Anderson Cancer Center 
produces grade 3-4 (RTOG-scale) mucositis in 94-100% of the patients according to the 
publications from this center [36, 55]. However, when tested in a multicenter study the 
same schedule was reported to give only a 47% incidence of grade 3-4 reactions [31]. 
Finally, decisions as to whether radiation reactions are tolerable or not and if a 
particular treatment schedule should be modified are highly dependent on physician 
experience and philosophies. At centers where there is a large experience with intensified 
treatments and where there are well developed supportive care programs, one may be 
willing to accept greater acute toxicity than in some other centers. 
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Fractionation parameters: studies in mouse and human mucosa 
Experimental studies on the upper aerodigestive tract mucosa have been performed on 
mouse lip and tongue Fractionation experiments covering a wide range of fraction sizes 
from 1 2 to 22 5 Gy as well as continuous and fractionated low dose rate and high dose rate 
experiments demonstrated characteristics typical for acutely responding tissues with α/β 
ratio s in the range of 5 8 to 16 4 Gy [1, 3, 24,72, 73] It also became clear from these data 
that reducing the dose per fraction below 2 Gy does not lead to a further increase in 
tolerance [1] Fractionation parameters of human normal tissues are generally obtained by 
retrospective analysis An exception is the clinical study by Denham et al [18] They treated 
patients with incurable head and neck cancers with fractionated radiotherapy using dose 
rates varying from 0 8 to 240 Gy/h For the human oropharyngeal mucosa they calculated 
an α/β ratio of 9 3 Gy (5 8-17 9, 95% CI) with patchy mucositis as the endpoint This 
corresponds well with the values found in mouse studies From these same data they 
derived a very short half-time for repair of sublethal damage (T1/2) of 15 nun (8 4-90, 95% 
CI) The mouse data indicate somewhat longer repair half-times in the range of 37-72 min 
[3, 24, 72] A recent study on mouse lip mucosa suggested a bi-exponential repair process 
with a long T1/2 of 150 min and a fast component of 27 min but with a large proportion 
(82%) of the damage being repaired by the fast component [73] Repair processes for these 
acute reactions can thus be considered to approach completion after 4-5 h However, there 
are clinical studies suggesting differently These studies have been reviewed by Bentzen et 
al [8] and include the RTOG studies 7913 and 8313 [15, 57], a study from the MD 
Anderson Cancer Center [32], and a study from the Center of Oncology in Waisaw [13] 
All four studies showed a decrease in the incidence of mucosal reactions when the interval 
between fractions given on a same day was increased, typically from around 4 h to around 
6 h The investigators compared the steepness of the dose-response curves from studies not 
involving incomplete repair with those derived from the above four studies It was shown 
from this comparison that Τ1/2 for human mucosa must be in the range of 2 to 4 h, 1 e 
longer than the values for mouse mucosa and much longer than the value derived by 
Denham et al although, admittedly, the corresponding 95% confidence intervals of the latter 
were fanly large (8 4-90 min) On the other hand, to our knowledge, this is the only clinical 
study specifically designed to address the question of repair kinetics Retrospective analysis 
of data fiom different clinical studies is flawed by many confounding factors Additional 
human data will be needed to resolve this issue 
The repopulation kinetics of the mouse mucosa have been studied by Ang et al [4] and 
by Dorr et al [25, 26] A substantial repopulation effect was observed after a lag time of 
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about 3 days from the start of treatment. This regenerative response increases progressively 
and accounts for about 1 Gy per day worth of recovery between days 7 and 10 in mouse lip 
[4]. Dörr et al. demonstrated that in mouse tongue epithelium repopulation can fully 
counteract the effect of five weekly doses of 2.5-3.5 Gy during week 2 and 3 of a course of 
daily fractionated irradiation [25, 26]. Another important finding was that the rate of 
repopulation depended on the level of damage. The endpoint in the study by Ang et al. was 
spotted mucositis, whereas that of Dörr et al. was complete denudation. This might explain 
the higher repopulation rates found by the latter group. 
Both investigators also addressed the issue of protraction and temporal distribution of 
radiation fractions. In mouse lip experiments 10 fractions were administered in 3 days 
(multiple fractions per day) or in 11 days (daily fractions) [4]. This led to a gain of about 
13 Gy for peak mucosal reactions, i.e. 1.6 Gy per day. When the same 10 fractions were 
administered in two short courses of five fractions given in 1.5 days with a rest period of 8 
days (overall time 11 days), an additional 5 Gy was recovered. This suggests that 
repopulation may be more efficient during a treatment-free period. Dörr [23] simulated split-
course treatments by delayed top-up doses following daily fractionated irradiation, thus 
introducing splits of 6 h to 13 days. He demonstrated that the rate of repopulation rapidly 
increases during fractionated radiotherapy but decelerates after cessation of treatment and 
suggested that it is the greater initial damage that stimulates more efficient repopulation. 
Data from Fletcher et al. indicate that human oropharyngeal mucosa can counteract the 
full daily dose at the end of a conventional course of radiation [29, 78]. Twenty patients 
were treated to doses of 55 Gy in 4-4.5 weeks with fraction sizes of 2.45-2.75 Gy. Three 
of them showed signs of mucosal healing during the last week of treatment. When the same 
dose was administered in 5-5.5 weeks (2-2.2 Gy daily dose) healing had begun in two of 
11 patients before completion of treatment. Further reduction of the daily dose to 1.83-2 Gy 
and protraction to 6-6.5 weeks allowed healing of the mucosa in six of eight patients during 
the final stages of treatment. These data suggest that human oropharyngeal mucosa can 
counteract about 1.8 Gy per day at the end of a 6-week course of irradiation. 
Van der Schueren et al. investigated the influence of multiple fractions per day and 
treatment gaps on mucosal proliferation in man [81]. In patients with advanced head and 
neck cancers conventional schedules to doses of 50 and 70 Gy were compared to split-
course schedules with three or four fractions daily. The fraction sizes used were 1.6 or 
2 Gy, overall treatment time was 4 to 7 weeks, and the total dose ranged from 60 to 
67.2 Gy. The most important parameter that was modified was the dose given in one 
treatment series. The first schedule consisted of two unequal radiation series: 48 Gy in 12 
days, followed by a second series of 19.2 Gy in 4 days after a 3-4 week interval. The 
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subsequent treatment schedules were divided in equal series: two times 30 Gy, three times 
22.4 Gy, and four times 16 Gy, all with 2 week intervals. The mucosal reactions were 
scored three or four times per week and with the last schedule (four times 16 Gy) even daily 
because of the short duration of reactions. The treatment-free intervals were long enough to 
allow for (nearly) complete healing between series. This, and the frequency of scoring gave 
detailed information allowing analysis of the mucosal reaction patterns for each of the series 
within these various split-course schedules. The investigators observed a linear relationship 
between the duration of spotted and/or confluent mucositis and the dose given per treatment 
series. This supports the notion that the healing time is a good indicator of the level of 
radiation damage at the tissue level. It was demonstrated that the duration of mucositis with 
conventional treatment to 50 Gy was about 5 days longer than would be expected with a 
split-course treatment of the same total dose. The most unusual schedule delivered 16 Gy in 
eight fractions over 2 days, repeated four times with 12 days intervals. Thus a total dose of 
64 Gy was delivered in 6 weeks. With this schedule the majority of patients did not 
transgress the level of spotted mucositis and the duration of reactions was very short. There 
were 18 fully évaluable "reaction cycles" where the patients were scored at least six times a 
week during the full reaction period. Only once in one patient a 2-day period of confluent 
mucositis was observed. 
Thus, both animal and human data indicate that discontinuous irradiation without 
increasing the total length of radiotherapy can allow for a more effective regeneration of the 
mucosa. However, such discontinuous irradiation may also have consequences for tumor 
response. 
In summary we have learned the following from studying mucosal reaction patterns in 
animals and patients: 1) The α/β value for mucositis is in the range of what can be expected 
for acutely responding tissues (5.8-16.4 Gy), but reduction of fraction dose below 2 Gy 
may not lead to further tissue sparing. 2) Short Τ1/2 values have been derived from animal 
experiments (37-72 min) and one clinical study (15 min) but retrospective analysis of other 
clinical data suggests longer Τ1/2 values. 3) The rate of repopulation increases progressively 
from the third day (in mice) of treatment and can counteract daily doses of about 1.8 Gy in 
man and up to 3.5 Gy in mice. 4) The rate of repopulation depends on the level of damage 
which may explain a more effective regeneration with discontinuous schedules with 
intensified dose delivery at the beginning of treatment. 
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Clinical studies on accelerated and hyperfractionated radiotherapy in head 
and neck cancer 
A search of the international English literature over the past 25 years revealed 62 
different schedules of accelerated and/or hyperfractionated radiotherapy which have been 
tested for definitive treatment of head and neck tumors. We have categorized these schedules 
into four groups: A) accelerated fractionation with moderate reduction of overall treatment 
time (33-40 days) and unchanged total dose; B) accelerated fractionation with overall 
treatment time < 33 days but > 17 days, usually with moderate reduction of total dose; 
C) accelerated fractionation with overall treatment time < 17 days and reduction of total 
dose; and D) hyperfractionation. This grouping was done merely to bring some order in this 
large number of studies and because treatment time appears to be the major determinant for 
total dose (Gy) 
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Fig. 3. Schedules of altered fractionation tested in the head and neck area, plotted as a 
function of total dose and overall treatment time [5, 6, 10, 11, 13, 15-17, 19-22, 
32, 34-37, 39-44, 47-50, 52-55, 57, 58, 60-63, 65-70, 74, 75, 77, 80-83]. 
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mucosal reactions. Each schedule has been interpreted with regard to acute mucosal toxicity 
according to the investigators' conclusions and categorized as "acceptable" or "severe 
mucosal morbidity requiring modification of the treatment schedule". Fig. 3 shows a 
scattergram of various schedules plotted as a function of total dose and overall time. Studies 
which combined radiotherapy with chemotherapy or surgery were excluded as well as 
papers without sufficient data on acute mucosal toxicity. If available, the median or mean 
values of actual delivered dose and overall treatment time are presented. Many papers 
however do not provide these data in which case the prescribed dose and time are used. 
A) Accelerated fractionation with moderate reduction of overall treatment time (33-40 
days) and unchanged total dose. This group includes four types of schedules: split-course: 
treatment is given twice or three times daily for 1-2 weeks followed by a rest period of 2-4 
weeks after which treatment is resumed; concomitant boost type schedules, giving the boost 
as a second daily fraction during part of the treatment, usually at the end; schedules which 
increase the weekly dose rate by treating during weekends; and schedules which increase the 
weekly dose rate by giving twice daily treatments continuously with small fraction size. We 
identified three schedules for which modification was recommended because of severe acute 
mucosal toxicity [17, 37, 54]. The schedules discussed in this section are diagrammatically 
represented in Fig. 4. 
Maciejewski et al. reported their experience with a schedule of pure acceleration, i.e. 
only reduction of the overall treatment time without change of the total dose or dose per 
fraction [54]. This was accomplished by giving single daily fractions of 2 Gy for 7 days a 
week over 5 weeks which allowed "ideal" interfraction intervals of 24 h between all 
fractions. They reported severe mucosal reactions (score > 15, composite scale) lasting 
longer than 3 weeks in 48% of the patients. Soft tissue necrosis in the oral cavity or 
oropharynx occurred in 21% of the patients within 7-12 weeks after the completion of the 
treatment which they considered to be consequential to the severe early reactions. Because 
of unacceptable toxicity dose per fraction was reduced to 1.8 Gy. Toxicity data of this 
modified schedule are not yet available. 
Another schedule which required some modification was presented under the acronym 
"HARDE": Hyperfractionated, Accelerated Radiotherapy with Dose Escalation [37]. This 
regimen prescribed two fractions per day on weekdays with escalating dose per fraction 
( 1.2 Gy week 1 and 2, 1.4 Gy week 3 and 4, 1.6 Gy week 5) and a single dose of 2 Gy on 
Saturdays to a total dose of 76 Gy in 5 weeks. The intervals between the fractions were at 
least 6 h. Acute mucosal reactions were described as "extremely brisk". All patients 
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Fig. 4. Dose accumulation as a function of time for four schedules with moderate 
reduction of overall treatment time 
developed confluent mucositis Two of 12 patients experienced marked prolongation of 
acute mucosal toxicity The investigators decided to delete the Saturday fractions, 
maintaining a dose > 70 Gy over a 5 5 week treatment course 
The third regimen producing excessive mucosal toxicity was a split-course schedule 
[17] Twice daily fractions of 1 8 Gy were administered with intervals of at least 6 h An 
initial 16 fractions were followed by a 5-12 day break, followed by a further 20-22 fractions 
to a total dose of 64 8-68 4 Gy over 5-6 weeks Ninety-six percent of patients developed 
confluent mucositis with a median duration of 7 weeks The actuarial rate of late 
complications was 47% at 3 years but the investigators were unable to find any relationship 
between the duration of acute mucositis and the development of late effects It was 
concluded that the schedule should be modified, mainly to reduce the risk of late 
complications but also to moderate early mucosal toxicity 
From these studies it can be concluded that the tolerance of the upper aerodigestive tract 
mucosa does not allow acceleration of treatment to less than 5 weeks without a reduction of 
total dose This applies in particular to continuous course schedules, which is best 
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exemplified by the study of Maciejewski et al using optimal interfraction intervals of 24 h 
[54] 
As demonstrated by the mouse studies, a possible gain might be obtained by the 
introduction of splits in the treatment This is not supported by the split-course schedule 
discussed above [16] although, admittedly, the main reason for modifying this schedule was 
the high rate of late complications Another split-course schedule was tested in EORTC-
study 22851 and compared with conventional radiotherapy [39] In the experimental arm 
72 Gy was delivered over 33 days Three daily fractions were given to a dose of 28 8 Gy 
in 8 days After a 12-14 day rest period a second course of 43 2 Gy was given in 11 days 
In this experimental arm grade 3-4 mucosal reactions (EORTC/RTOG scale) were observed 
in 67% of the patients during treatment More importantly, these reactions were still present 
in 70% of patients 6 weeks after treatment Grade 3 late mucosal sequelae (deep mucosal 
necrosis or major mucosal edema requiring tracheostomy) occurred in 13% of the patients in 
the accelerated arm compared to 5% in the control arm Also, they occurred significantly 
more rapidly in the accelerated arm The investigators did not find evidence for a 
consequential effect in their material although the prolonged duration of mucositis and the 
more rapid occurrence of late sequelae do suggest such a mechanism It was concluded that 
the boundaries of acceptable acute and late tolerance were reached and recommended that the 
schedule should be modified to reduce late toxicity It was felt that "acute toxicity did not 
represent a major obstacle to the feasibility of accelerated schemes" 
The EORTC-schedule delivered the same total dose as in Maciejewski's study in a 
slightly shorter overall time Dose specification was the same The first one was found to 
approach the limits of acute tolerance but still acceptable whereas the latter clearly exceeded 
mucosal tolerance with severe consequential damage Distribution by T-stage was more or 
less the same in both studies but the EORTC-study included more advanced nodal disease 
Therefore, any differences in treatment volume would probably be disadvantageous for the 
EORTC-study Maciejewski's study included more larynx and hypopharynx tumors As 
demonstrated before, the radiation tolerance of the mucosa at these sites is better than in the 
oropharynx, at least with conventional treatment It is therefore unlikely that the differences 
in tolerance between these two studies are due to differences in treatment volume or tumor 
site In the EORTC-study the interval between fractions was only 4 h which may not be 
optimal according to Bentzen's review [8] Thus, if there is truly a difference in acute 
tolerance, the explanation should come from the split-course design of the EORTC-study 
This, on the other hand, is not confirmed by the other split-course schedule discussed 
above It is also possible that we are confronted with a different subjective interpretation of 
toxicity data by different investigators 
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В) Accelerated fractionation with overall treatment time < 33 days but > 17 days, 
usually with moderate reduction of total dose Two schedules in this group were judged to 
be unacceptable with respect to acute toxicity, one split-course and one continuous schedule 
The first one delivered eight fractions of 0 9 Gy per day with 2 h intervals over 5 days [60] 
After a rest period of 2 weeks an identical series was given to a total dose of 72 Gy over 4 
weeks Confluent mucositis occurred in 45% of patients and confluent mucositis with 
ulceration in another 26% In 23% of all patients severe necroses were noted within the first 
6 months after treatment Apart from the high dose given in a very short time, the 
interfraction intervals were most probably too short to allow for sufficient repair of sublethal 
damage in this schedule The second schedule is another example of pure acceleration [43] 
The total dose (66 Gy) and dose per fraction (2 Gy) were unchanged relative to conventional 
treatment and the overall time was reduced to 22-25 days by delivering two fractions per day 
with an interval of at least 6 h Detailed data on mucositis were not given in this paper but it 
was stated that most patients developed confluent mucositis and that many of these reactions 
persisted for weeks and in some cases for months It was also stated that "the clinical 
outcome in these patients was not unlike that resulting from supralethal dose described half a 
century ago" It was the excessively prolonged acute reactions in some patients and the high 
incidence of grade 4 (RTOG scale) late effects (8/41 patients) that caused the Head and Neck 
tumour group in British Columbia to discontinue the use of this particular accelerated 
regime 
Fig 5 shows these two schedules and some other schedules [10, 11, 16, 19] in this 
group which were considered as tolerable The two schedules with the higher total dose are 
the ones exceeding mucosal tolerance confirming the conclusion that reduction of treatment 
time to less than 5 weeks also requires reduction of the total dose Apparently this reduction 
must be in the order of 15% Doses of around 60 Gy m 3-4 weeks are within the limits of 
tolerance It should also be noted that the window is narrow differences in time or dose of 
only a few days or a few Grays can tilt the balance 
Two schedules in this group delivered doses of about 70 Gy in slightly less than 5 
weeks and were judged as acceptable [5, 77] One, relatively small study, included patients 
with oral cavity and oropharynx tumors giving 70 3 Gy over 32 days [5] The investigators 
judged the mucosal reactions as acceptable However, at 4 months after radiotherapy still 
20% of the patients had "major symptoms" lelated to mucositis which indicates that this 
schedule is at the margin of tolerance The other study included only patients with 
nasopharynx tumors and the total dose of 71 4 Gy, given over 30 days, was limited to the 
primary tumor site [77] Mucositis in the nasopharynx is probably better tolerated because 
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Fig. 5. Dose accumulation as a function of time for six schedules with overall treatment 
time < 33 days but > 17 days. 
there is no food passage and possibly also because this mucosa is of a different histological 
type. 
C) Accelerated fractionation with overall treatment time < 17 days and reduction of total 
dose This type of very accelerated schedules has already been tested in the seventies and 
early eighties but has only later been taken into large scale clinical studies [20] To deliver a 
significant dose in a time as short as 2 weeks requires administration of at least three 
fractions per day To accomplish this goal during normal working hours the interval 
between fractions can not be more than 4 h. This, in fact, was the case with all the earlier 
studies where intervals of 3-4 h were used One of the earliest reports on such a schedule 
was by Svoboda [74] He treated various tumor types like breast, bronchus, bladder and 
also larynx and hypopharynx carcinomas. Dose per fraction varied from 1.6 to 2 3 Gy but 
was usually in the order of 1.7-1 8 Gy for the patients with head and neck tumors [75] 
Total dose varied between 50 and 55 Gy with treatment times of 10-14 days. There were no 
treatments during weekends. Results in 59 évaluable patients were described The 
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investigator mentioned that "A mucositis with fibrinous pseudomembranes was observed 3-
4 weeks after the start of treatment and the reactions had healed by the end of the second 
month" Of 19 patients in whom the oral cavity was treated, two had delayed mucosal 
healing and two others had persistent superficial ulceration of the tongue It was concluded 
that the early reactions were moderate and well tolerated This approach was adopted by 
others [35, 52, 63, 67] but conclusions about tolerance differed markedly Peracchia et al 
treated 22 patients with doses of 48-56 Gy, 2 Gy per fraction, over 8-12 days [67] They 
describe a confluent mucositis that developed after 2-3 weeks which decreased only very 
slowly within 4-5 months and led to necrosis in 15 (68%') patients Nine patients even died 
because of this complication without evidence of local tumor recurrence The slow healing 
of the mucosa followed by necrosis (already after 4-8 months in 12 patients) strongly 
suggests that the latter is a consequential effect As a possible explanation for this disastrous 
outcome it was suggested by the investigators that repair of sublethal damage in the 
oropharyngeal mucosa may not be complete 4 h after a dose of 2 Gy A slightly lower dose 
per fraction of 1 8 Gy was reported to produce acceptable mucosal toxicity in a small study 
of nine patients [35] Exactly the same schedule caused "unacceptably severe acute 
reactions" according to other investigators [50] This latter statement was, however, not 
accompanied by any data The largest published experience with this schedule is by Olmi et 
al [63] They treated 161 patients with tumors of the oral cavity, oropharynx, and paranasal 
sinuses Of these, 124 received a total dose of 48-52 Gy, 2 Gy per fraction, over 11-12 
days Peak mucosal reactions occurred on average 2 weeks after the start of treatment with 
complete recovery after 6-10 weeks in most cases There were five patients with transient 
mucosal ulceration healing within 6 months No relationship was found between acute and 
late sequelae The interval between fractions in this study was also 4 h The acute reactions 
were classified as "brisk but still tolerable" Lower doses per fraction of 1 5-1 8 Gy but also 
with short intervals (3-4 h) were used in a more recent study [52] A total dose of 47 5-
54 Gy was delivered over 12-20 days Severe confluent mucositis was reported m 18/58 
patients (31%) with denudation of the mucosa in some Modifications including further 
reduction of total dose and dose per fraction and field shrinking were recommended 
Dische et al recently published the results of a randomized multicenter trial of CHART 
versus conventional radiotherapy in head and neck cancer [20] CHART (continuous, 
hyperfractionated, accelerated radiotherapy) deliveied fractions of 1 5 Gy three times per 
day including Saturday and Sunday to a total dose of 54 Gy in 36 fractions over 12 days 
The intervals between the fractions were at least 6 h Five-hundred fifty-two patients were 
randomized to the experimental arm and 366 to the conventional arm The moibidity related 
to these schedules was well documented Confluent mucositis occurred in 73% of the 
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CHART cases compared with 43% in the conventional arm (66 Gy in 33 fractions over 6.5 
weeks). Persistence of mucositis for > 6 weeks occurred in 30% of the patients and > 8 
weeks in 2% with CHART. In fact, reactions in the CHART cases tended to settle sooner 
than in the patients treated conventionally. The incidence of late superficial or deep mucosal 
ulceration was significantly lower with CHART. This regimen proved to be acceptable with 
regard to acute reactions and was so far associated with a reduced severity in a number of 
late morbidities compared to conventional treatment. 
The acute toxicity of the CHART schedule, although enhanced, is clearly within 
acceptable limits. When a higher dose per fraction (1.8-2.0 Gy) and shorter interfraction 
intervals (3-4 h) are used, investigators seem to disagree about tolerance. Apparently with 
these very accelerated schedules only small variations in treatment time, dose, dose per 
fraction, and possibly also interfraction intervals can shift enhanced but still acceptable 
mucosal morbidity towards very severe and intolerable toxicity. 
D) Hyperfractionation. Lowering the dose per fraction to 1.1-1.2 Gy and delivering 
two fractions per day enables dose escalation to about 80 Gy [15, 40]. For oropharynx 
tumors EORTC study 22791 compared 80.5 Gy given in twice daily fractions of 1.15 Gy 
over 7 weeks with a conventional treatment to 70 Gy [40]. Objective mucosal reactions were 
more severe in the experimental arm (67% of patients with confluent mucositis) but 
tolerable. The incidence of late effects was the same in both arms and in particular there was 
no increase of late mucosal sequelae with hyperfractionation. This study was preceded by a 
pilot investigation which tested fraction doses of 1.15 to 1.25 Gy [41]. The lowest dose per 
fraction allowed the total dose of 80.5 Gy to be given with more tolerable acute mucosal 
reactions whereas 1.25 Gy twice daily was clearly too toxic. A similar experience was 
reported from the MD Anderson Cancer Center using hyperfractionation mostly for larynx 
and hypopharynx carcinomas [32]. Initially a dose per fraction of 1.2 Gy was used with 4 h 
intervals to a median total dose of 76.8 Gy. Later the protocol was amended to try to 
decrease a high rate of acute reactions and to maximize the tolerance of late reacting tissues. 
The interfraction interval was increased to 6 h and for patients receiving wide field nodal 
irradiation the dose per fraction for the initial fields was reduced to 1.1 Gy. The planned 
total dose was not changed which implies a treatment protraction of 2 days. A significant 
reduction of mucositis was observed after these amendments. The incidence of confluent 
mucositis was reduced from 52 to 37%. Only 4% of the patients had persistent mucositis 
(i.e. mucositis of 6 weeks duration or greater) versus 14% of the patients treated in the 
earlier period. To what extent the increase of the interfraction interval and the reduction of 
fraction dose with consequent increase of overall time have contributed to the increased 
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tolerance cannot be differentiated Because, with the lower fraction dose, a trend towards 
worse local control for T3 tumors was observed, the 1 2 Gy per fraction throughout has 
been reinstated for this subgroup Apparently, although maybe approaching the limits of 
tolerance, this schedule is tolerable This is confirmed by the publications from the 
University of Florida group who also have a large experience with this schedule [66] and by 
RTOG-study 83-13 [15] The latter study involved a dose escalation in four steps 67 2 Gy, 
72 0 Gy, 76 8 Gy, and finally 81 6 Gy Interestingly, in this study no dose-response 
relationship could be demonstrated for grade 3-4 (RTOG-scale) acute reactions It may well 
be that the treatment piotraction which accompanied this dose escalation was sufficient to 
allow for complete compensation by mucosal repopulation With each step 2 extra treatment 
days with two 1 2 Gy fractions were added Bentzen et al calculated an average protraction 
of 2 8 days (averaging out extra weekends included to finish therapy) for each increase of 
4 8 Gy [8] This, according to their calculations, is equivalent to 4 48 Gy in 2 Gy fractions 
which then corresponds with 1 6 Gy/day This is in agreement with the estimation of daily 
recovery equivalent to 1 8 Gy/day based on data from Fletcher which was discussed earlier 
[29, 78] 
With this type of hyperfractionated schedules small differences in the daily dose rate of 
0 2 Gy can cause observable differences in mucosal reactions, this being particular relevant 
during the first part of the treatment At the end of the treatment the mucosa is able to almost 
fully recover the daily dose An escalation of the rate of daily dose delivery might thus 
improve tolerance, for example using 1 1 Gy fractions during the first part of the treatment 
and 1 3-1 4 Gy fractions at the end This principle was explored by Haran et al who 
escalated the fraction dose from 1 2 Gy in the first weeks to 1 6 Gy in the last week of 
treatment [37] In fact the same is done with concomitant boost type schedules [13, 36, 47, 
55] 
In summary 1) With continuous course schedules acceleration to treatment times less 
than 5 weeks requires reduction of the total dose to below 70 Gy Doses of around 60 Gy in 
3-4 weeks are within the limits of tolerance It may be advantageous to escalate the rate of 
dose delivery during treatment and deliver higher daily doses towards the end when the 
mucosa is most actively repopulating 2) If mucosal tolerance can be improved by 
introducing a split, the gain is probably small, at least with clinically ìelevant temporal dose 
distributions Split-course schedules and also the very short continuous schedules often 
require that three fractions per day are delivered Intervals between fractions should be 
sufficiently long, 1 e > 6 h, at least foi late reacting tissues but possibly also for mucosa to 
allow for repair of sublethal damage to approach completion This means that such 
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treatments can only be delivered if the treatment facility is operational beyond normal 
working hours 3) Escalating dose by adding treatment days to a 6-7 weeks schedule of 
hyperfractionation does not seem to significantly enhance mucosal reactions 4) And finally, 
once approaching the limits of tolerance small variations in treatment time, dose, dose per 
fraction, and possibly also interfraction intervals can shift enhanced but still acceptable 
mucosal morbidity towards very severe and intolerable toxicity 
Altered fractionation: does the upper aerodigestive tract mucosa limit 
treatment intensification? 
The rate of dose delivery is the most important determinant for early radiation reactions 
It seems fair to conclude that, relative to a conventional treatment of 7 weeks, the maximum 
achievable gain in treatment time is 2 weeks with the mucosa being the limiting tissue Any 
further acceleration requires a reduction of dose Manipulations with the temporal 
distribution of dose, fraction dose, and optimization of interfraction intervals can improve 
tolerance but we foresee no possibilities for a significant further intensification of the 
existing accelerated schedules by such measures 
Dose escalation by hyperfractionation however does not seem to be directly limited by 
early mucosal reactions Late reacting tissues are more likely to limit further intensification 
of these schedules 
Important to remember is that tumors retain many characteristics of the normal tissue 
from which they originate It is therefore not surprising that the differential between the 
fractionation sensitivity of squamous cell carcinomas and mucosa is small Some hints for 
this relationship were found after a retrospective analysis of 286 patients which 
demonstrated a nonsignificant trend towards higher local tumor failure rates in patients who 
had lower scores of acute mucositis [32] A similar analysis of data from EORTC trial 
22791 which compared hyperfractionation and conventional fractionation for oropharynx 
carcinomas, on the other hand did not reveal convincing evidence for the existence of such a 
relationship [9] 
Future directions 
Randomized studies have proven the effectiveness of altered fractionation for head and 
neck tumors Improvements of the loco-iegional control rate aie in the range of 5-23% [2, 
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16, 20, 39, 40, 65]. As we have reached the limits of tolerance, how must we proceed to 
further improve treatment outcome? Different strategies can be explored: 1) Application of a 
potent agent which can prevent or diminish radiation mucositis might permit further 
intensification of radiotherapy for head and neck carcinomas. 2) Combination of altered 
fractionation with modifiers of other resistance mechanisms, e.g. hypoxic sensitizers. 
3) Individual tailoring of the treatment schedule according to patient and tumor 
characteristics. 
Besides for eventual treatment intensification, any agent that can ameliorate radiation-
induced mucositis is of value for diminishing discomfort to the patient. Unfortunately, 
drugs with sufficient potency have yet to be identified. Sucralfate, an aluminum hydroxide 
complex of sulfated sucrose introduced for the treatment of gastric ulcers was found to 
alleviate bowel discomfort during and after pelvic irradiation [38]. The effectiveness of this 
agent in the head and neck area was tested in six randomized studies but only one showed a 
positive result [7, 28, 30, 51, 56, 59]. Spijkervet suggested that gram-negative bacteria and 
possibly also yeasts colonizing the oral tissues may be involved in the pathogenesis of 
radiation induced mucositis [71]. Elimination of these microorganisms from the oral cavity 
and oropharynx might then reduce mucositis. In a randomized study which accrued 221 
évaluable patients, lozenges containing polymyxin E, tobramycin and amphotericin were 
compared with placebo [76]. A small subset of patients (14%) was treated with the CHART 
schedule whilst the others were treated conventionally. Slightly over 60% of patients in both 
groups developed spotted mucositis. The incidence of confluent mucositis was lower in the 
experimental arm (14% vs. 27%). The relative mucosal surface affected by spotted or 
confluent mucositis was 30% versus 40% in the control arm (median values). Although 
these differences were statistically significant, this antimicrobial prophylaxis is probably not 
effective enough to allow intensification of fractionation schedules. Unfortunately no details 
were given on the CHART patients in this study. Also patients with tumors at various sites 
were included, half of them having larynx or hypopharynx carcinomas. It is not clear 
whether at these sites adequate concentrations of the drugs are obtained by this particular 
mode of topical administration and whether the same microorganisms are involved at the 
different sites. Benzydamine hydrochloride is a nonsteroidal drug that possesses analgetic, 
anti-inflammatory and antimicrobial properties. In a small randomized study including a total 
of 43 patients benzydamine as a prophylactic rinse was shown to reduce the area involved 
by mucositis [27]. However, within this small patient group there was considerable 
heterogeneity with regard to both tumor localization and dose delivered and the results must 
be interpreted with some caution. Other potentially useful agents include silver-nitrate, 
prostaglandins, granulocyte-macrophage colony stimulating factor (GM-CSF), and 
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immunoglobulins but these have not yet been tested in randomized studies. So far, none of 
these measures seem compelling enough to be recommended as standard practice. 
Accelerated radiotherapy aims to counteract tumor cell repopulation whereas 
hyperfractionation schedules were designed to overcome intrinsic radioresistance. The third 
important resistance mechanism is hypoxia. A next step to create a greater differential 
between normal tissue effects and tumor response is to combine altered fractionation with 
modifiers of oxygenation. The series of consecutive Danish Head and Neck Cancer Studies 
(DAHANCA) nicely demonstrates how consequent and stepwise incorporation of 
radiobiological principles in clinical trials has lead to improved tumor control. In the 
randomized DAHANCA-5 study it was shown that radiotherapy with the hypoxic sensitizer 
nimorazole improved loco-regional control in supraglottic and pharyngeal carcinomas from 
33 to 49% (5-year actuarial rate) [64]. In the most recent DAHANCA-7 trial reduction of 
treatment time from 6.5 to 5.5 weeks plus nimorazole gave an additional improvement from 
44 to 58% (3-year actuarial rate) [65]. Two mechanisms underlying tumor hypoxia are 
recognized. Chronic hypoxia results from the limited diffusion distance of oxygen in tissue 
[79], whereas acute or transient hypoxia is caused by local fluctuations in tumor blood 
perfusion [12]. "ARCON" combines accelerated radiotherapy with carbogen to reduce 
chronic tumor hypoxia and with nicotinamide to reduce acute hypoxia. Testing of this 
strategy in the clinic has recently started and preliminary results are very encouraging. In a 
phase II study of 62 patients with stage ІП-І laryngeal carcinomas an actuarial 2-year local 
control rate of 92% was obtained [45]. 
The third strategy involves tools to identify which individual tumors or classes of 
tumors are most effectively treated by either of the new radiotherapy approaches. However, 
predictive assays with sufficient discriminating power are not yet available. It is also 
becoming clear that mechanisms determining the radiation response of tumors are not acting 
independently and it is very likely that often a combination of factors is responsible for 
treatment failure. Considering the complexity of the mechanisms involved and the 
heterogeneity within tumors, it is unlikely that radiation response can be predicted with 
sufficient accuracy by the value of a single parameter. We must therefore develop assays for 
simultaneous analysis of multiple resistance factors, if possible, supplemented by assays of 
normal tissue sensitivity to obtain a "predictive profile". It is not realistic to expect that in the 
near future all individual patients can be subjected to such extensive testing. The approach 
may however lead to the identification of categories of tumors that are best treated by certain 
new strategies. 
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Abstract 
The feasibility of carbogen breathing and the intake of nicotinamide in combination with 
radiation therapy is currently being tested for clinical application A dependable and 
convenient system for carbogen breathing is presented which can be easily combined with 
techniques for immobilization of the patient The proposed method ensures adequate 
breathing of carbogen 
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Introduction 
Recent experimental studies have led to a renewed interest in the clinical use of agents 
to reduce hypoxia in malignant tumors. These studies have shown the effectiveness of both 
nicotinamide and carbogen breathing on the differential response to radiation of malignant 
and normal tissues in fractionated X-ray treatments [4]. The results are promising and 
encourage the clinical use of these two modalities, which are by themselves non-toxic in 
man, in phase I and II trials. Dische et al. recently presented a pilot study on the effect of 
carbogen breathing on mainly lung carcinomas and demonstrated a remarkably good local 
control [2]. Also the EORTC has shown interest in the use of carbogen breathing in 
combination with the intake of nicotinamide and accelerated fractionation regimens 
(ARCON) and initiated a phase I-II study for several tumor types [3]. Some centers have 
already started to study the feasibility of carbogen breathing and the intake of nicotinamide 
in combination with radiation therapy, and preliminary results were presented in the first 
ARCON Newsletter [t]. 
At the Institute of Radiotherapy of the University Hospital Nijmegen, phase I-II 
studies, which combine carbogen breathing and nicotinamide with radiation therapy, were 
initiated for patients with stage ΙΠ and IV head and neck tumors and patients with malignant 
brain tumors. For this category of patients it was necessary to combine a reliable and 
convenient way of carbogen breathing with a proper method for immobilization of the 
patient during irradiations. Breathing through a scuba-diving rubber mouth piece with the 
nose clipped (to prevent the inspiration of air), as proposed by Dische et al. [2], was tried 
by patients and healthy volunteers. Although the method is shown to be feasible it was an 
unpleasant experience, especially for patients with tumors in the upper airway and/or 
disturbed respiratory reflexes. Clipping the nose obstructs the air passage through the nose 
and hinders the normal swallowing act, in particular when patients are in a supine position. 
Furthermore, it is difficult to adjust the constant flow of carbogen (recommended, 10 1/min) 
to personal needs and it can increase expiratory resistance. 
To improve patient comfort during irradiations, we developed a new method of 
carbogen breathing that can be used in combination with conventional fixation techniques in 
the head and neck region. 
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Materials and Methods 
Requirements to be met by our system were to enable normal swallowing during 
carbogen breathing and to regulate carbogen delivery to the individual's needs with minimal 
resistance from the breathing system In addition, such a breathing system should permit the 
use of immobilizing casts Normal swallowing is only possible with unobstructed nasal 
passage Therefore, a disposable anesthetic face mask (Artec Ine Indianapolis, USA) with a 
silicone cuff, covering both mouth and nose, was selected The silicone cuff is designed in 
such a way that only slight pressure seals the breathing space airtight These face masks are 
available in three sizes To transport the gas from the high pressure (30-150 atmos) 
reservoir to the patient, a scuba-diving breathing regulator (Scubapro, Brussels, Belgium), 
which consists of two stages, is used The first stage is attached to the reservoir and reduces 
pressure to approximately 9 atmos An intermediate pressure hose leads the gas to the 
second stage which further reduces pressure to a breathable level This second stage is 
connected to the face mask (Fig 1) which is incorporated in the immobilizing cast A two-
step pressure reduction is utilized for safety and to allow the use of a "demand valve type" in 
the second stage This second stage can be tuned in such a way that the slightest demand for 
air is responded to almost immediately without any extra effort The valves in this system 
prevent flow of carbogen during exhalation such that no extra expiratory effort is needed 
Both Orfit (Ortomed, Schiedam, The Netherlands) and Scotch (3-M, Zoeterwoude, The 
Netherlands) material, used for fabrication of immobilizing casts, appeared to be appropriate 
for combining with the anesthetic mask Both materials are heated before use and melt 
together with the plastic of the anesthetic mask The fixating casts ensure a tight coverage of 
mouth and nose by the anesthetic mask and offer sufficient pressure to guarantee an airtight 
breathing space without leakage of air (Fig 2) 
Effect of carbogen breathing on arterial O2 pressure and hemoglobin 
saturation 
The effect of carbogen breathing on arterial O2 pressure (pC>2) and hemoglobin O2 
saturation was tested in three male healthy volunteers Before and after a 5-min period of 
carbogen breathing, utilizing the above presented method, blood samples were obtained 
from the femoral arteries Only a slight increase was observed in the saturation of 
oxyhemoglobin This was expected since the saturation of hemoglobin by oxygen is already 
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Fig. 1. The disposable anesthetic face mask with the special silicone caff connected to 
the second stage of the scuba-diving breathing regulator. 
nearly complete in arterial blood of healthy persons. The increase of dissolved oxygen in 
plasma, however, was significant. Initial pC>2 values were 13.8, 16.0, and 14.0 kPa in the 
three volunteers and rose to 74.2, 82.5, and 76.6 kPa, respectively, after carbogen 
breathing. The breathing of carbogen was experienced as rather convenient not only by the 
volunteers but also by the 25 patients that have entered the studies to date. Only one patient 
with severe claustrophobia was unable to cope with the procedure. 
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Fig. 2. Carbogen breathing patient. The anesthetic face mask covers both nose and 
mouth and is incorporated in an immobilizing cast (Scotch). The mask is 
connected to the reservoir with carbogen by the scuba-diving breathing 
regulator. 
Conclusion 
Radiation oncologists who participate in the new EORTC ARCON study [3] or in any other 
clinical study which combines radiation therapy with carbogen breathing, need a reliable and 
convenient method of administering the gas. A method based on professional diving 
equipment was designed which can be combined with standard fixation techniques in the 
head and neck region and minimizes discomfort during treatment. Of the 25 patients who 
have entered our studies to date, only one was unable to cope with the breathing system, 
and this was due to extreme claustrophobia. The influence of 5 min carbogen breathing by 
- 7 2 -
Carbogen breathing 
the presented method on arterial O2 pressure was tested in three healthy volunteers. The 
desired effect, i.e. an increase in arterial O2 pressure, was easily achieved. 
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Abstract 
The feasibility and early toxicity of radiotherapy with carbogen breathing and 
nicotinamide was tested in 74 head and neck cancer patients. Forty patients with laryngeal 
and hypopharyngeal tumors were treated with an accelerated schedule combined with 
carbogen alone (16) or with carbogen and nicotinamide (24). Thirty-four patients with far 
advanced unresectable tumors of the oral cavity and oropharynx received conventional 
radiotherapy with carbogen (16) or with carbogen and nicotinamide (18). 
Some enhancement of skin reaction was observed with nicotinamide but this remained 
well within the limits of tolerance. With the accelerated regimen there was increased severity 
of mucosal damage expressed as confluent mucositis in 95% of the patients which required 
healing times of 3-4 months in four patients. Eventually restoration of the mucosal lining 
was complete in all cases. Nausea and vomiting are the most frequent side-effects of 
nicotinamide and were reported by 60 and 36% of the subjects, respectively. In 26% this 
was reason to discontinue drug intake. Severe renal dysfunction was associated with 
nicotinamide intake in two patients of this study and in one other patient who presented 
later. 
It is our conclusion that radiotherapy combined with carbogen and nicotinamide is a 
safe treatment with manageable side-effects. We recommend not to give nicotinamide 
concomitantly with nephrotoxic medication or to patients who have impaired renal function. 
Preliminary tumor control rates are encouraging and clinical testing will be continued. 
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Introduction 
It is well recognized that hypoxia is an important factor determining the radiation 
response of squamous cell carcinomas. In man, the existence of hypoxia and its relationship 
to the outcome of radiation therapy has been demonstrated in carcinomas of the head and 
neck and uterine cervix [5, 9, 18, 19]. Randomized clinical trials with hyperbaric oxygen 
and hypoxic cell radiosensitizers have shown significantly improved local control rates in 
carcinomas of the head and neck [7, 8, 21, 22]. However, these approaches have not gained 
general acceptance. The side-effects of many radiosensitizers hamper their clinical use 
although some newer drugs are less toxic. Delivery of radiation in hyperbaric oxygen is a 
demanding technique and often hypofractionation has been used, but this is currently not 
considered optimal because of reduced sparing of late reacting normal tissues. 
Two mechanisms underlying tumor hypoxia are recognized. Chronic hypoxia results 
from the limited diffusion distance of oxygen in tissue [27], whereas acute or transient 
hypoxia is caused by local fluctuations in tumor blood perfusion [2, 3]. Agents that modify 
tumor microcirculatory function may reduce acute hypoxia. The amide derivative of vitamin 
B3, nicotinamide, has recently received attention in this respect [11, 16]. It was suggested 
that nicotinamide could further enhance the sensitizing effect of carbogen as a method to 
eliminate chronic hypoxia [24]. Polarographic studies have shown that carbogen (95% O2 + 
5% CO2) breathing can increase the oxygen partial pressure and reduce chronic hypoxia in 
patients with head and neck tumors [20]. Relative to radiation treatment in air without the 
drug, enhancement ratios in the order of 1.8 have been obtained for treatment with carbogen 
and nicotinamide in mouse tumors [17]. 
Another important factor determining the radiation response of tumors is cellular 
repopulation. There is evidence from clinical studies that patients with head and neck 
carcinomas may benefit from accelerated fractionated irradiation to counteract repopulation 
of tumor clonogens which occurs during the course of treatment [1, 26]. Results of 
randomized trials are expected soon. 
Rojas et al. proposed the strategy of combining accelerated radiotherapy with carbogen 
and nicotinamide (ARCON) to overcome both the compensating effect of tumor 
repopulation and chronic and acute hypoxia [25]. This is a report on the feasibility and 
toxicity of this approach in patients with carcinomas of the head and neck. 
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Patients and Methods 
Design of the study Two categories of patients were eligible for the study One 
category includes patients with laryngeal (stage III-IV) and hypopharyngeal (stage II-IV) 
tumors receiving primary radiotherapy as larynx conserving treatment The other category of 
patients had far advanced unresectable tumors, mostly of the oral cavity and oropharynx and 
were referred for palliative radiotherapy It was planned to first treat 15 patients with 
carbogen alone in each category After this had been shown to be feasible and without 
severe direct toxicity, nicotinamide was added Since experience was previously obtained 
with an accelerated schedule in laryngeal cancers [13], it was decided to build on this 
experience and to add carbogen and nicotinamide as second and third steps, respectively 
For the oral cavity and oropharyngeal tumors carbogen breathing and nicotinamide were 
added stepwise to a conventional radiation schedule The patients with laryngeal and 
hypopharyngeal tumors were analyzed separately from those with oral cavity and 
oropharyngeal tumors because normal tissue effects as well as treatment outcome are 
expected to be different in the two groups 
This work was approved by the local ethical committee 
Patients Seventy-four consecutive patients were entered into the study over the period 
November 1992 until February 1995 Inclusion criteria were an age over 18 years, WHO 
performance status of 0-2, no severe heart or lung disease, no severe liver or kidney 
function disturbances, no severe stridor, no distant metastases, and written informed 
consent Another six patients were eligible but refused participation Thirteen patients were 
ineligible for the following reasons poor performance status (9), severe cardiac and 
pulmonary disease (4), claustrophobia (1), and Rendu-Osler-Weber disease with severe 
anemia (1) The patients entered in the study had a mean age of 57 years (range 27-82 
years) There were 60 men and 14 women All patients had squamous cell carcinomas 
except one with a mucoepidermoid carcinoma of the larynx Three patients had two 
concurrent primary tumors in the head and neck area Two other patients had recurrent 
disease after surgical treatment Characteristics of the patients, their tumors, and the 
treatment are shown in Table 1 
Radiotherapy The primary tumor and bilateral neck nodes were irradiated through 
lateral opposed photon beams (4 and 6 MV) The inferior border was generally placed just 
superior to the arytenoids for oral cavity and oropharyngeal tumors For tumors of the 
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Table 1. Number of patients according to treatment (RT = radiotherapy, conv -
conventional, ace = accelerated, carb = carbogen, nie = nicotinamide) and site of 
primary disease and clinical stage (UICC1992 staging system). 
Treatment 
No. patients 
Mean age (range) 
S t a g e T x 
Τι 
T 2 
T 3 
T 4 
No 
N1 
N2a 
№b 
N2c 
N3 
not classatile 
Site of primary 
oral cavity 
oral tongue 
floor of mouth 
oropharynx 
soft palate 
tonsillar fossa 
base of tongue 
pharyngeal wall 
maxillary sinus 
auditory canal 
larynx 
supraglottic 
glottic 
hypopharynx 
pyriform sinus 
postcncoid 
No. patients 
receiving 
chemotherapy 
Conv RT 
+ carb 
16 
55 (41-76) 
-
2 
-
5 a 
8 
3 
2 
-
1 
8 
1 
1 
1 
1 
5 
7a 
1 
-
1 
-
-
8 
Conv 
+ carb 4 
18 
RT 
• nie 
53 (27-73) 
1b 
-
-
8 C 
9 
3 
4 
-
5 
4 
2 
-
3 
5b 
1 
5° 
3 
1 
-
-
-
8 
Ace RT 
+ carb 
60 
16 
(39-82) 
-
-
7 
8 
1 
6 
7 
-
2 
1 
-
-
-
-
-
-
10 
3 
2 
1 
Acc RT 
+ carb + nie 
24 
60 (41-78) 
-
-
7 
13 
4 
11 
5 
-
1 
7 
-
-
-
-
-
-
11 
5 
6 
2 
2 
aOne patient with synchronous second primary of soft palate (T2). 
bOne patient with synchronous second primary of pyriform sinus (T2). 
cOne patient with synchronous second primary of vallecula 0Ί). 
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larynx and hypopharynx the inferior border was placed just above the shoulders. After 30-
40 Gy, an off-cord reduction was made and the posterior cervical chains were treated with 
lateral appositional electron beams. The mid- and lower-neck nodes were treated with an 
anterior photon field. In some cases a posterior field was added to supplement the dose in 
the posterior midcervical chains. The boost dose was delivered through reduced lateral or 
oblique opposed portals combined, when necessary, with an electron beam to boost nodal 
areas overlying the spinal cord or larynx. Conventional radiotherapy was given in fractions 
of 2 Gy, five times a week. Total dose was 68 Gy for gross disease and 44 Gy for the areas 
treated electively. The overall treatment time was 46-48 days. With the accelerated schedule, 
the dose per fraction remained 2 Gy but treatment time was reduced by 10 days by giving 
two fractions per day during the last one and a half weeks of treatment. Intervals between 
fractions were at least 6 h. 
Sensitization of the laryngeal cartilage has been reported after radiotherapy in 
hyperbaric oxygen [8]. A 10% reduction of the total dose in a subsequent study of 
hyperbaric oxygen reduced the laryngeal complications to a level seen with treatment in air 
[7]. Since a similar effect might be expected from normobaric carbogen with nicotinamide, 
the maximal permissible dose to the larynx was reduced from 70 to 64 Gy and, as a 
consequence, the tumor dose for primaries of the larynx and hypopharynx did not exceed 
this limit. Involved nodes received 68 Gy. Because a decrease in the tolerance of the rat 
spinal cord of -20% was observed when radiation was combined with carbogen and 
nicotinamide [6], the total dose to the spinal cord was not higher than 40 Gy. Dose 
specification was according to Report 29 of the ICRU [12]. 
Carbogen breathing: Scuba-diving equipment was used for carbogen delivery. This 
system transports the gas from the reservoir to the patient by way of a two-step pressure 
reduction. The second stage of the breathing regulator is connected to a disposable 
anesthetic face mask which is incorporated in the immobilizing cast. Details of this breathing 
system have been described earlier [14]. Carbogen breathing commenced 4 min before start 
of irradiation of the macroscopic tumor localizations and was continued throughout the 
treatment. During the 4-min preirradiation breathing time fields were set up and uninvolved 
supraclavicular nodes were treated. The preirradiation breathing time and total breathing time 
were recorded. 
Nicotinamide: Nicotinamide, dissolved in fruit juice, was administered orally 1.5 h 
before irradiations. On days when two fractions were given, only one dose of nicotinamide 
was taken before the first treatment. Initially the daily dose was 6 g. After April 1994, when 
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more pharmacokinetic data became available, this was changed to a weight-adjusted dose of 
80 mg/kg with a maximum of 6 g. 
Monitoring during treatment: Blood pressure and heart rate were measured on the first 5 
treatment days just before and after irradiations. This was discontinued after the first 20 
patients because no changes had been observed. 
Blood samples were drawn once a week for blood cell counting and hemoglobin 
concentration measurement. When hemoglobin concentrations fell below 7 mmol/1 this was 
corrected by blood transfusions. Initially, serum liver enzymes, sodium, potassium, urea, 
and creatinine were determined before and in the last week of the treatment. Later this was 
also done weekly during the course of irradiation. 
Weekly assessment of the acute mucosal and skin reactions started in the first week of 
treatment and continued during treatment and thereafter until the lesions started to heal. 
Patients were then seen once every 2 or 3 weeks until healing was complete. The reactions 
of mucosa and skin and dysphagia were scored as shown in Table 2. Since 1987 this 
Table 2. Scores for mucosal and skin reactions. 
Acute reactions Score 
Mucosa 
Dysphagia 
Skin 
normal 
slight redness 
severe redness 
spotted mucositis 
confluent mucositis < 50% of irradiated surface 
confluent mucositis > 50% of irradiated surface 
no complaints 
complaints, no medication 
medication needed 
liquid feeding 
tube feeding 
normal 
slight redness 
severe redness 
dry desquamation 
moist desquamation < 50% of irradiated surface 
moist desquamation > 50% of irradiated surface 
0 
1 
2 
3 
4 
5 
0 
1 
2 
3 
4 
0 
1 
2 
3 
4 
5 
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scoring system is applied routinely to all patients receiving radiotherapy to the head and neck 
area in our institute. 
Additional treatment: Eighteen patients received chemotherapy prior to radiation 
treatment. In most cases this consisted of cisplatin weekly for one to six courses. One 
patient was treated with three courses of methotrexate, bleomycin, vinblastine, and cisplatin. 
All these patients had far advanced unresectable tumors. After radiotherapy two patients 
underwent neck dissections for residual nodal disease. 
Statistics: Fisher's exact probability test was used to test the significance of differences 
in acute toxicity scores between the groups. Average duration of mucosal and skin reactions 
was compared by the i-test. 
Results 
Carbogen breathing: The measurements of blood pressure and heart rate before and 
after carbogen breathing were discontinued after no apparent changes were observed in the 
first 20 patients. Six of the 74 patients were unable to continue carbogen breathing 
throughout the entire course of irradiation. Two patients underwent a tracheostomy, one 
because of edema and the other because of tumor progression; the other four patients 
experienced sensations of suffocation, sometimes accompanied by extreme hyperventilation. 
Preirradiation breathing time was less than 4 min in 1.2% (25/2123) of radiation sessions 
but never less than 3 min. It was longer than 6 min in 5.8%, usually due to delays in the 
treatment set up. The total breathing time was more than 15 min 6.7% of times, mostly 
when complicated techniques were used to limit the dose to the spinal cord. 
Nicotinamide: The most common side-effects from nicotinamide were nausea and 
vomiting, reported, respectively, by 25 (60%) and 15 (36%) of the 42 patients taking the 
drug. Ten patients were nauseous after the first dose of nicotinamide. Often these 
complaints were unresponsive to anti-emetics including ondansetron. Eleven patients (26%) 
discontinued the intake of nicotinamide due to severe nausea and vomiting. One patient was 
under treatment when adjustments of nicotinamide dose were made from 6 g to individual 
weight-corrected doses. In this patient nausea disappeared when the dose was reduced from 
6 g to 4 g (80 mg/kg). Apart from this one patient we observed no differences in side-effects 
between patients taking 6 g and those taking 80 mg/kg. Five patients reported flushing 0.5-
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2 h after ingestion One patient showed signs of depression which disappeared within a few 
days after nicotinamide was discontinued One patient refused to continue nicotinamide 
intake because of the bad taste No serum liver enzyme disturbances related to nicotinamide 
were observed Twelve patients had isolated elevation of γ-glutamyl transpeptidase (γ-GT), 
mostly already before start of treatment, which was ascribed to alcohol abuse 
Two patients developed severe renal dysfunction following nicotinamide 
administration Patient 1 received daily doses of 6 g and patient 2 received 5 5 g Both 
patients complained of nausea and vomiting and patient 2 also had severe diarrhea This was 
reason to discontinue the drug in both patients Both were admitted to the hospital a few 
days later with dehydration and renal dysfunction Patient 1 was known to suffer from 
type I diabetes mellitus and hypertension and concomitant medication consisted of insulin, 
lisinopnl (angiotensin converting enzyme -ACE- inhibitor), bisoprolol (selective ß-blocker), 
carbasalatcalcium and ondansetron Patient 2 was on metoclopramide, oxazepam, and an 
antacid Prior to the start of radiotherapy he received six weekly cycles of cisplatin, 
70 mg/m2 Maximum recorded serum levels of creatinine were 2290 μηιοΐ/ΐ in patient 1 and 
1096 μπιοΐ/ΐ in patient 2 Renal function recovered with rehydration and bicarbonate 
administration in both patients In addition, both patients developed thrombopenia of 
uncertain etiology Patient 1 also had moderate and transient elevation of liver enzymes 2 
weeks after discontinuation of nicotinamide She fully recovered and could resume 
radiotherapy Patient 2 had an episode of ventricular tachycaidia, possibly as a result of 
electrolyte disturbances He had a large unresectable tumor and progression of disease 
already under chemotherapy and it was decided to stop further radiation treatment because of 
the very poor prognosis 
Radiotherapy Three patients did not complete the planned radiation tieatment One 
patient died from a massive bleeding in the tumor, one patient developed distant metastases 
during loco-iegional treatment and the third patient as mentioned above had rapid tumoi 
progression, renal complications and deterioration of general condition Total treatment 
duration exceeded 48 days in four of the 34 patients tieated according to the conventional 
schedule Reasons were renal complications (6 days), tracheostomy (I day), machine 
breakdown (1 day), holiday, not compensated for (1 day) Of the 40 patients tieated by the 
accelerated schedule only one surpassed the maximum allowed treatment time of 38 days 
with a single day because of a holiday that was not compensated for 
Early reactions of mucosa and skin The scores foi acute radiation îeactions duiing and 
after treatment are shown in Figs 1 and 2 Only the highest scores are shown because 
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Chapter 5 
scores 1 and 2 have limited clinical significance and are nearly always followed by more 
severe reactions For the group of patients treated with conventional radiotherapy and 
carbogen (C) confluent mucositis occurred in 81% of the cases, and with addition of 
nicotinamide (C+N) this was 83% Average duration was 3 5 (C) and 5 1 (C+N) weeks 
(p = 0 08, f-test) The accelerated schedule caused confluent mucositis in all but two cases 
(95%) with an average duration of 6 3 (C) and 6 7 (C+N) weeks Prolonged duration of 
confluent mucositis, ι e persisting more than 6 weeks after the end of treatment, was 
observed in four patients after the accelerated regimen In all cases healing was complete 
within 3-4 months after treatment Tube feeding was needed in 29% of patients with oral 
cavity and oropharynx tumors and in 26% of patients with laryngeal and hypopharyngeal 
tumors with no significant differences between patients receiving carbogen alone and those 
receiving carbogen and nicotinamide Objective and functional mucosal reactions were not 
more severe for patients who received chemotherapy prior to irradiation (data not shown) 
Addition of nicotinamide appeared to somewhat increase skin reactions The 
conventional schedule with carbogen caused moist desquamation in four of 16 patients 
(25%) and in 10 of 18 patients (56%) who received also nicotinamide (p = 0 06, Fisher's 
exact test) With the accelerated schedule this was nine of 16 (56%, C) and 15 of 23 (65%, 
C+N) Generally the skin healed rapidly within 3 weeks except in one case m which it 
required 7 weeks This patient was in the conventional schedule with carbogen and 
nicotinamide 
Loco-regional tumor control All 39 patients with tumors of the larynx and 
hypopharynx who finished the planned course of irradiation had complete disappearance of 
loco-regional tumor at 6 weeks after the end of treatment Actuarial loco-regional control at 
one year was 86%, with 21 patients being in follow-up at least a year after treatment Thirty-
two patients with oral cavity and oropharynx tumors completed the treatment, of whom 20 
(63%) had complete regression of disease at 6 weeks The one-year actuarial loco-regional 
control rate for this group was 41%, with 23 patients in follow-up one year or more after 
treatment 
Discussion 
Carbogen breathing by the method described previously [14] appears to be feasible and 
well tolerated, even by patients with large tumors in the upper aero-digestive tract Only four 
of 74 patients were unable to cope with the procedure because they experienced sensations 
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of suffocation, in some cases with hyperventilation which is caused by the carbon dioxide 
component of the gas Polarographic O2 measurements in metastatic lymph nodes from head 
and neck carcinomas showed that breathing time before optimal oxygenation was 4 nun or 
less in 19 of 20 patients [20] It was also demonstrated that tumor рОг starts to decline after 
12-18 min of carbogen breathing [4] Thus, irradiations are best delivered between 4 and 
15 min after the start of carbogen breathing when tumor oxygenation is at its peak level 
This was accomplished m 92% of our radiation sessions 
Reported side-effects of nicotinamide are nausea, vomiting, flushing, facial erythema, 
headache, fatigue, cutaneous reactions, and rare events of liver toxicity [29] Doses of 
nicotinamide of up to 6 g daily were described as reasonably safe and associated with a low 
incidence of side-effects In our experience, with doses of 6 g per day or 80 mg/kg per day, 
nausea and vomiting occurred frequently and necessitated discontinuation of the drug in 
26% of patients Gastrointestinal symptoms were also reported in other clinical pilot studies 
three of six patients with head and neck cancer [30], two of six patients with breast cancer 
[23], and m two of 16 patients with malignant gliomas [28] The mechanism by which these 
symptoms are produced is not clear there may be a systemic effect or topical irritation of the 
gastrointestinal mucosa In the latter case, an alternative route of administration might reduce 
these unpleasant side-effects Severe renal dysfunction was associated with nicotinamide 
intake in two patients When this article was being finalized a third patient presented with 
this complication, also after previous treatment with cisplatin Thus, two patients received 
previous (cisplatin) and one concomitant (ACE-inhibitor, carbasalatcalcium) nephrotoxic 
medication This, in combination with decreased renal flow due to hypovolemia as a result 
of nicotinamide-induced vomiting and decreased oral fluid intake, may well be the cause of 
rapidly developing renal failure Any direct renal toxicity from nicotinamide can, however, 
not be excluded It was shown that the drug inhibits renal clearance of 51CrEDTA and l 2 5 I -
lodohippurate in mice [10] These effects were dose-related and evident at doses from 
400 mg/kg upwards which is considerably higher than the doses clinically applied Only 
one previous case of renal toxicity in man has been reported by Zackrisson et al [30] This 
patient received two daily doses of 6 and 3 g He had a known cardiomyopathy and was on 
treatment with an ACE-inhibitor as was one of our patients The patient had nausea and 
vomiting and developed hypotension with elevation of serum creatinine and liver enzymes 
The plasma concentrations of nicotinamide and its metabolites suggested that renal 
elimination was impaired Possibly in patients with compromised renal function 
(nephrotoxic medication, hypovolemia) nicotinamide accumulates in the plasma to a level at 
which it can aggravate renal dysfunction and may lead to seveie renal failure 
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Unlike our experience with glioma patients [28], we did not observe nicotinarrude-
related hepatic toxicity in this category of head and neck cancer patients One of the patients 
with renal complications had moderate elevation of liver enzymes but this was unlikely to be 
ι elated to nicotinamide intake because it started 2 weeks after discontinuation of the drug 
Apparently it was the combination with anti-epileptics and steroids that induced liver toxicity 
in the glioma patients 
Nowadays with the availability of megavoltage equipment the incidence of severe skin 
reactions is low We previously reported an 8% rate of moist desquamation for conventional 
radiotherapy with total doses of 68-70 Gy [13] In this study we observed rates of 25% (C) 
and 56% (C+N) This increased skin reaction is not unexpected as enhancement ratios of 
13-15 were estimated for rodent skin [17] With the accelerated schedule alone 50% of 
patients develop moist desquamation [13] When carbogen and nicotinamide are added there 
is only a small further increase to 56% (C) and 65% (C+N) which is not statistically 
significant Apart from one case, skin lesions healed rapidly The early reacting tissue of 
greater clinical significance is the mucosal membrane With the conventional schedule, 81% 
(C) and 83% (C+N) of patients in this study developed confluent mucositis of the oral 
cavity and oropharynx This corresponds to the 78% rate that we observed when these areas 
were treated with radiotherapy alone [15] Acceleration of treatment causes confluent 
mucositis in up to 90% of patients with laryngeal cancer, with complete healing within 6 
weeks after completion of treatment in all cases [13] In this study confluent mucositis 
occurred in 95% of patients (C and C+N) However, four patients had healing times of up 
to 4 months A possible increase of severity of mucosal damage by addition of carbogen and 
nicotinamide may well be expressed as delayed recovery We believe that the acute radiation 
toxicity as observed with the current regimen is acceptable but we do not advocate further 
intensification of treatment as this might lead to non-healing lesions and consequential late 
effects 
In conclusion, it is our opinion that radiotherapy combined with carbogen and 
nicotinamide is a safe treatment with manageable side-effects No expensive additional 
equipment is needed and it requires hardly any extra machine time Certain precautions 
should be taken, however, especially with regard to nicotinamide administration We 
recommend that nicotinamide should not be given to patients presenting with elevated serum 
creatinine levels and it should not be given concomitantly with nephrotoxic medication 
During treatment, renal function should be monitored at least once a week and twice weekly 
in patients at risk (e g those who were treated previously with cisplatin) Adequate oral 
intake is demanded When serum creatinine rises above normal levels, nicotinamide should 
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be discontinued immediately and proper hydration must be secured, if necessary by 
intravenous infusion. 
Possibly, side-effects of nicotinamide can be limited when individual dose adjustments 
are made or when an alternative route of administration is used. Currently we are monitoring 
nicotinamide plasma levels in our patients to assess whether proper levels are obtained when 
treatment is given on a day to day routine basis and also to investigate if these are related to 
the observed side-effects. 
Preliminary tumor control rates are promising and the approach offers potentials for 
larynx preservation. In the category of far advanced tumors proposed for palliative 
treatment, complete regressions were achieved and sustained in a significant proportion of 
the patients. We expect to increase the effectiveness of the treatment for this particular 
category with introduction of the accelerated schedule. Our experience with ARCON so far 
is encouraging and we will proceed with further clinical testing. 
Acknowledgements 
The authors would like to thank J. Liefers for excellent assistance with patient care and 
data management and J.F.M. Wetzels, Department of Medicine, Division of Nephrology, 
for advice. 
- 8 9 -
Chapter 5 
References 
1. Ang, K.K., Peters, L J., Weber, R.S et al. Concomitant boost radiotherapy schedules 
in the treatment of carcinoma of the oropharynx and nasopharynx. Int J. Radiât. 
Oncol. Biol. Phys. 19 1339-1345, 1990. 
2. Brown, J M : Evidence for acute hypoxic cells in mouse tumours and a possible 
mechanism of reoxygenation. Br. J. Radiol. 52. 650-656, 1979 
3. Chaplin, D.J., Durand, R.E and Olive, P.L Acute hypoxia in tumors: implication for 
modifiers of radiation effects. Int. J. Radiât Oncol. Biol. Phys. 12: 1279-1282, 1986 
4. Falk, S.J., Ward, R. and Bleehen, N.M The influence of carbogen breathing on 
tumour tissue oxygenation in man evaluated by computerised рОг histography. Br J. 
Cancer 66· 919-924, 1992. 
5. Gatenby, RA., Kessler, H.В., Rosenblum, J S. et al. Oxygen distribution in 
squamous cell carcinoma metastases and its relationship to outcome of radiation 
therapy. Int. J. Radiât. Oncol Biol. Phys. 14: 831-838, 1988. 
6 Haustermans, K., van der Kogel, A J., Vanacker, В and van der Schueren, E 
Influence of combined use of nicotinamide and carbogen on rat spinal cord radiation 
tolerance. Radiother Oncol. 31: 123-128, 1994. 
7. Henk, J M Late results of a trial of hyperbaric oxygen and radiotherapy in head and 
neck cancer: a rationale for hypoxic cell sensitizers9 Int J. Radiât. Oncol. Biol. Phys 
12: 1339-1341, 1986 
8 Henk, J M , Kunkler, P.B. and Smith, С W Radiotherapy and hyperbaric oxygen in 
head and neck cancer. Lancet n. 101-103, 1977. 
9 Hockel, M., Knoop, С, Schienger, К. et al Intratumoral рОг predicts survival in 
advanced cancer of the uterine cervix Radiother. Oncol 26 45-50,1993 
10. Honess, D.J. and Bleehen, N.M. Effects of the radiosensitising agent nicotinamide on 
relative tissue perfusion and kidney function in C3H mice Radiother. Oncol 27. 140-
148, 1993. 
11. Horsman, M.R., Chaplin, DJ. and Brown, J M Tumor radiosensitization by 
nicotinamide: a result of improved perfusion and oxygenation. Radiât Res 118: 139-
150, 1989 
- 9 0 -
Radiotherapy with carbogen and nicotinamide 
12. International Commission on Radiation Units and measurements: Dose specification for 
reporting external beam therapy with photons and electrons. Report 29. ICRU 
Publications, Washington, DC, 1978. 
13. Kaanders, J.H.A.M., van Daal, W.A.J., Hoogenraad, W.J. and van der Kogel, A.J. 
Accelerated fractionation radiotherapy for laryngeal cancer, acute and late toxicity. Int. 
J. Radiât. Oncol. Biol. Phys. 24: 497-503, 1992. 
14. Kaanders, J.H.A.M. and van der Maazen, R.W.M. A convenient and reliable method 
for carbogen breathing in man. Radiother. Oncol. 29: 341-343, 1993. 
15. Kaanders, J.H.A.M., Pop, L.A.M., Muytjens, H.L., Bruaset, I. and van Daal, 
W.A.J. Topical administration of antimicrobial agents to prevent irradiation mucositis 
of the oral cavity and oropharynx: a pilot study. Radiât. Oncol. Invest. 2: 283-290, 
1995. 
16. Kelleher, D.K. and Vaupel, P.W. Nicotinamide exerts different acute effects on 
microcirculatory function and tissue oxygenation in rat tumors. Int. J. Radiât. Oncol. 
Biol. Phys. 26: 95-102, 1993. 
17. Kjellen, E., Joiner, M.C., Collier, J.M., Johns, H. and Rojas, A. A therapeutic benefit 
from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-
ray treatments. Radiother. Oncol. 22: 81-91, 1991. 
18. Lartigau, E., Le Ridant, A.-M., Lambin, P. et al. Oxygenation of head and neck 
tumors. Cancer 71: 2319-2325, 1993. 
19. Lartigau, E., Vitu, L., Haie-Meder, С et al. Feasibility of measuring oxygen tension in 
uterine cervix carcinoma. Eur. J. Cancer 28A: 1354-1357, 1992. 
20. Martin, L., Lartigau, E., Weeger, P. et al. Changes in the oxygenation of head and 
neck tumors during carbogen breathing. Radiother. Oncol. 27: 123-130, 1993. 
21. Overgaard, J., Hansen, H.S., Andersen, A.P. et al. Misonidazole combined with split-
course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: 
report from the DAHANCA 2 study. Int. J. Radiât. Oncol. Biol. Phys. 16: 1065-1068, 
1989. 
22. Overgaard, J., Sand Hansen, H., Lindel0v, B. et al. Nimorazole as a hypoxic 
radiosensitizer in the treatment of supraglottic larynx and pharynx carcinomas. First 
- 9 1 -
Chapter 5 
report from the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85 
Radiother Oncol 20 (Suppl 1) 143-149,1991 
23 Pigott, К , Dische, S and Saunders, M I The addition of carbogen and nicotinamide 
to a palliative fractionation schedule for locally advanced breast cancer Br J Radiol 
68 215-218, 1995 
24 Rojas, A Radiosensitization with normobanc oxygen and carbogen Radiother Oncol 
20 (Suppl 1) 65-70, 1991 
25 Rojas, A , Joiner, M С and Denekamp, J Extrapolations from laboratory and 
preclinical studies for the use of carbogen and nicotinamide in radiotherapy Radiother 
Oncol 24 123-124, 1992 
26 Saunders, M I , Dische, S , Grosch, E J et al Experience with CHART Int J 
Radiât Oncol Biol Phys 21 871-878, 1991 
27 Thomlinson, R H and Gray, L H The histological structure of some human lung 
cancers and the possible implications for radiotherapy Br J Cancer 9 539-549, 1955 
28 Van der Maazen, R W M , Thyssen, H O M , Kaanders, J H A M et al 
Conventional radiotherapy combined with carbogen breathing and nicotinamide for 
malignant gliomas Radiother Oncol 35 118-122,1995 
29 Zackheim, H S , Vasily, D В , Westphal, M L and Hastings, С W Reactions to 
niacinamide J Am Acad Dermatol 4 736-737, 1981 
30 Zacknsson, В , Franzén, L , Henriksson, R et al Acute effects of accelerated 
radiotherapy m combination with carbogen breathing and nicotinamide (ARCON) Acta 
Oncol 33 377-381, 1994 
- 9 2 -
CHAPTER 6 
ADMINISTRATION OF NICOTINAMIDE DURING A 
FIVE- TO SEVEN-WEEK COURSE OF RADIOTHERAPY: 
PHARMACOKINETICS, TOLERANCE, AND COMPLIANCE 
Johannes H.A.M. Kaanders 
Michael R.L. Stratford 
Janine Liefers 
Madeleine F. Dennis 
Albert J. van der Kogel 
Willem A.J. van Daal 
Anamaria Rojas 
Reprinted from: Radiother. Oncol. 43: 67-73, 1997 
with permission from Elsevier Science 
Chapter 6 
Abstract 
Nicotinamide was administered daily as a liquid formulation to head and neck cancer 
patients receiving a 5- to 7-week course of radiotherapy The pharmacokinetics, compliance, 
and tolerance of this drug formulation were studied. 
Blood samples were drawn and nicotinamide levels determined in 40 head and neck 
cancer patients On the first treatment day serial samples were obtained followed by daily 
samples at the time of irradiation during the first and last full weeks of the treatment Side-
effects of nicotinamide were monitored. 
In all patients peak concentrations greater than 700 птоІУтІ could be obtained 0.25-3 h 
(mean- 0 83 ± 0 73 h) after drug intake. During the first week of treatment plasma levels at 
the time of irradiation were adequate in 82% of the samples. This decreased to 59% in the 
last week of treatment which can be partly attributed to reduced compliance. The most 
important side-effect of nicotinamide was nausea with or without vomiting occurring in 65% 
of the patients. Severe side-effects were associated with high plasma concentrations over 
subsequent days. Tolerance improved after a 25% reduction of the dose in six of seven 
patients but plasma levels at the time of irradiation fell below 700 nmol/ml in four out of six 
of these patients. 
In conclusion, peak plasma concentrations above the 700 nmol/ml level were obtained 
in all patients but these concentrations could not be reproduced during the entire course of 
the treatment m a significant portion of the subjects. Side-effects of nicotinamide are 
associated with plasma concentrations and tolerance can be improved by a moderate 
reduction of dose 
-94-
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Introduction 
Nicotinamide is currently being assessed in clinical trials as a modifier of acute 
perfusion-hmited tumor-hypoxia This compound can reduce the intermittent closure of 
blood vessels in experimental rodent tumors [2,7] and consequently decrease hypoxic-cell 
radioresistant [6, 10] In addition, nicotinamide has been shown to enhance the sensitizing 
effect of carbogen [1, 12, 131, which overcomes the sparing effect of chronic diffusion-
limited hypoxia [16] With fractionated radiation schedules to mouse tumors, relative to 
radiation treatments in air without the drug, enhancement ratios in the order of 1 3-1 9 have 
been obtained for the combination of carbogen and nicotinamide [3, 12, 14, 15] 
Experimentally, plasma levels of 700 nmol/ml of nicotinamide are required at the time of 
irradiation to obtain a sensitizing effect [8, 15] Initial studies in healthy human volunteers 
showed that peak plasma levels of 800-1600 nmol/ml could be obtained after oral intake of 
6 g [8, 19] Horsman et al showed that for maximal radiosensitization tumors should be 
irradiated at the time of peak drug levels [8] 
The current clinical practice is to prescribe the drug on a weight adjusted basis and 
adequate plasma levels can be obtained in patients with oral doses of 80 mg/kg per day [9, 
18] In a recent study performed on a small number of patients undergoing CHART and 
given this dose of nicotinamide over 12 consecutive days, the drug was well tolerated but 
large inter-patient variations were seen both with regard to the maximum plasma 
concentration (Cmax) obtained and the time taken to reach this peak (Tmax) Peak levels were 
reported to range from 400 to 1400 nmol/ml with Tmax values from 0 8 to 4 h, but in the 
four patients in which repeated assessments were made at various times during the course of 
radiotheiapy the kinetic parameters were reproducible [9] However, there are no reliable 
pharmacokinetic and toxicity data with prolonged daily administration of high doses of 
nicotinamide during a 5- to 7-week course of radiotherapy and information on patient 
compliance is also lacking 
Although nicotinamide was suggested as a relatively non-toxic agent with a low 
incidence of side-effects even at the dose levels required for tumor radiosensitization [20], in 
our experience gastrointestinal complaints occur frequently In a previous study 60% and 
36% of the patients had nausea and vomiting, ìespectively, and in 26% this was reason to 
discontinue diug intake [11] Till now clinical studies have failed to demonstrate a 
ielationship between side-effects and nicotinamide plasma levels [18] 
We therefore decided to investigate if adequate nicotinamide plasma levels could be 
obtained in head and neck cancer patients enrolled in a study combining radiotherapy with 
carbogen breathing and nicotinamide and whether such levels were maintained throughout 
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the course of treatment. We also aimed to study whether the use of a liquid formulation of 
the drug improves the pharmacokinetic parameters of Cmax and/or Tmax and whether there is 
a relationship between plasma levels and the incidence and severity of toxic side-effects. 
This paper reports on data obtained in 40 patients undergoing either conventional or 
accelerated radiotherapy. 
Materials and Methods 
Patients: In our institute head and neck cancer patients with stage III-IV disease and 
also stage II hypopharyngeal cancer are currently being enrolled in a study combining 
radiotherapy with carbogen breathing and nicotinamide, details of which have been 
described previously [11]. Inclusion criteria are an age over 18 years, WHO performance 
status of 0-2, no severe heart or lung disease, no severe liver or kidney dysfunction, no 
severe stridor, no distant metastases, and written informed consent. From February 1995 to 
March 1996, after approval from the local ethical committee, 40 consecutive patients 
consented to have plasma samples drawn for determination of nicotinamide levels. There 
were 28 men and 12 women. Mean age was 61 years with a range of 41-82 years. 
Radiotherapy: Nine patients were treated by a conventional schedule and 31 by an 
accelerated fractionation schedule. Conventional radiotherapy was given in fractions of 
2 Gy, five times a week to a total dose of 68 Gy. Overall treatment time was 46-48 days. 
With the accelerated schedule the total dose was 64-68 Gy while dose per fraction remained 
the same and treatment time was reduced by 10 days by giving two fractions per day during 
the last 1.5 weeks of the treatment. The interval between the two fractions per day was 6 h. 
Some patients were hospitalized when they were treated twice daily because of travelling 
distance. 
Nicotinamide administration: Nicotinamide (Pharmachemie, Haarlem, The 
Netherlands), dissolved in fruit juice was administered orally 1.5 h before irradiation. After 
the pharmacokinetic data of the first 22 patients were analyzed, the interval was changed to 
1 h for the following 18 patients. A light meal, if taken at least 1 h before drug intake, was 
allowed. On days when two fractions were given, only one dose of nicotinamide was 
administered before the first treatment. The daily dose was 80 mg/kg to a maximum of 6 g. 
Since November 1995 a dose reduction to 60 mg/kg was introduced for patients with severe 
side-effects. Sixteen patients have been treated with this approach. If a dose reduction was 
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applied, nicotinamide was discontinued during one day prior to this to allow complete 
elimination of the drug in case accumulation had occurred 
Sample acquisition and analysis of nicotinamide concentrations On the first treatment 
day serial samples were taken usually through an intravenous cannula inserted in the arm 
An initial 5 ml of blood was discarded before the actual sample was collected On 
subsequent days blood was drawn by way of a venous puncture Five-ml samples were 
collected in hepannized tubes and immediately stored at 4°C Plasma was separated by 
centrifugaron (3000 χ g, 10 min) within 8 h of sampling and then stoied at -20°C prior to 
analysis Nicotinamide concentrations were determined in methanol extracts of plasma using 
high performance liquid chromatography [17] From all patients a full profile was obtained 
on the first day of treatment Sampling times on the first day were at 0, 0 25, 0 5, 1, 1 5, 2, 
3,4, 6, and 12 h after nicotinamide ingestion and the residual level was measured after 24 h 
(C
r e s
) One or 1 5 h after intake of the second dose another sample was collected Because 
of the frequent sampling on these first 2 days, patients were hospitalized during this time 
Thereafter samples were obtained daily during the first and last full weeks of the treatment at 
the time of irradiation, ι e 1 or 1 5 h after nicotinamide intake In addition, if nicotinamide 
dose was reduced, plasma samples were collected on at least 3 consecutive days starting on 
the first day of dose reduction 
Monitoring during treatment At each time of sampling blood pressure and heart rate 
were recorded During the course of treatment the patients were seen by both the attending 
radiation oncologist and, separately, by the research assistant at least once a week and more 
frequently if necessary, e g when side-effects occurred The patients were asked if any 
adverse events had occurred and they were specifically asked if they had experienced nausea 
and/or vomiting If they reported vomiting they were asked to specify when this occurred 
and how often Anti-emetics (metoclopramide, ondansetron) were pi escribed when 
necessary Side-effects of nicotinamide were considered severe if they led to a 
discontinuation of the drug or a reduction of the daily dose Gastrointestinal bleeding in one 
patient and renal dysfunction in another patient were felt to be possibly related to 
nicotinamide and also scored as severe 
Statistics For each patient the plasma levels obtained at the time of irradiation during 
the first full week were plotted and a lineai least-squares regression fit was done If there 
was a positive and significant (p < 0 05) correlation ot plasma levels with time, the patient 
was consideied to accumulate nicotinamide with daily administiation A discnminant 
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analysis was done to examine which pharmacokinetic parameters predicted best for 
nicotinamide toxicity All statistical analyses were done on a Macintosh computer using the 
Statistica 4 0 software package 
Results 
Tolerance The reported side-effects are listed in Table 1 Nausea with or without 
vomiting was reported by 65% of the patients Often these complaints were unresponsive to 
anti-emetics including ondansetron Eight patients experienced no side-effects at all while 16 
patients had side-effects that were considered as severe Nine patients discontinued 
nicotinamide intake because of side-effects, eight because of nausea and one because of 
renal toxicity Five patients discontinued intake of the drug for other reasons three patients 
went off study because of very poor compliance with the treatment protocol, one patient 
stopped nicotinamide in the fourth week of treatment because of the poor taste and 
dysphagia due to irradiation-mucositis, and in one case it was decided to stop at day 4 
because of pre-existent renal disturbances Of the 16 patients treated since November 1995, 
seven had a dose reduction to 60 mg/kg because of severe nausea Only one of these 16 
patients finally discontinued nicotinamide intake because of the side-effects in contrast to 
eight of the 19 patients treated previously (excluding the five patients that stopped 
nicotinamide for other reasons) 
There was no indication of an effect of nicotinamide on blood pressure or pulse 
Table 1. Nicotinamide side-effects in 40 patients 
Side-effect No. of patients 
nausea 26 
vomiting 13 
Mushing 7 
dizziness 6 
epigastric pain 3 
gastrointestinal bleeding 1 
renal dysfunction 1 
emotional disturbances 1 
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Fig. 1. Scatterplot of C
max
 versus T
max
 including all 40 patients 
First day nicotinamide plasma profile- C
m a x
 and T
m a x
 for each individual are shown in 
Fig. 1 Mean and median C
m a x
 were 1154 nmol/ml and 1088 nmol/ml with a standard 
deviation (SD) of ± 326 nmol/ml and a range of 752-2041 nmol/ml Thus, in all patients a 
minimal level of 700 nmol/ml could be obtained Mean and median T
m a x
 weie 0 83 h and 
0 51 h (SD + 0 73 h, range 0.25-3 h) T
m a x
 was equal or less than 1 h in 33 of the 40 
cases Fig. 2 illustrates the mean of the pharmacokinetic profiles obtained on the first day of 
treatment of all 40 patients The profiles of two individual patients are added in the figure to 
illustrate the inter-individual variability which is laigest during the first hour after 
nicotinamide intake One patient has a very high C
m a x
 with short T
m a x
 whereas the other 
has a relatively low C
m a x
 and long T
m a x
. With the accelerated radiation schedule the second 
treatment of the day is given 7-8 h after nicotinamide intake at which time the interpolated 
mean plasma level was about 500 nmol/ml Mean and median C
r e s
 were 66 nmol/ml and 
53 nmol/ml (SD ± 62 nmol/ml, range 0-221 nmol/ml) 
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Fig. 2. Nicotinamide (nie) plasma concentrations as a function of time after intake 
Mean of 40 patients with standard deviations The dotted lines represent two 
individual patients one with high C
max
 and short T
max
 and the other with low 
Стал and long T
max 
Nicotinamide plasma levels during first and last weeks of treatment Fig 3 shows the 
individual and mean plasma levels at the time of irradiation during the first and last full 
weeks of the treatment Some patients started radiotherapy on a Thursday, in those cases 
nicotinamide levels were determined in the first full week but also on the first 2 treatment 
days before and these are also shown in the figure Nicotinamide levels measured after dose 
reduction are not included At the start of the treatment 179 of 219 values (82%) were above 
the desired 700 nmol/ml and nine of 40 patients had lower values more than once In 11 of 
37 patients a linear least-squares regression fit to the values obtained at the time of 
irradiation during the first full week indicated that accumulation of nicotinamide occurred 
with daily administration In three cases the regression analysis could not be carried out 
because drug intake was already discontinued in the first week Accumulation was not 
correlated with C
r e s
, ι e patients with a ìelatively high residual 24-h level after the first drug 
dose did not necessarily show drug accumulation 
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On average, plasma concentrations decreased towards the end of the treatment During 
the last week 55 of 94 (59%) values were above the 700 nmol/ml level and nine of the 19 
patients who continued nicotinamide intake until the end of the treatment and without a dose 
reduction had values that fell below this level more than once 
Fig 4 shows the nicotinamide plasma concentrations for the seven patients who had a 
dose reduction. It includes the levels obtained in the first week with doses of 80 mg/kg, the 
levels directly after reduction to 60 mg/kg, and those obtained in the last week of the 
treatment. One patient continued having severe side-effects and stopped nicotinamide intake 
In two patients levels greater than 700 nmol/ml were obtained and reproduced daily with the 
60 mg/kg dose, three others produced levels in the 400-700 nmol/ml range, and in one 
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Fig. 3. Nicotinamide plasma concentrations at the time of irradiation during the first and 
last week of the treatment. Individual values of 40 patients are represented by the 
circles. Closed and open symbols represent values obtained during 
hospitalization and at the outpatients' department respectively. Horizontal bars 
indicate mean values. Dashed horizontal line indicates 700 nmol/ml level. 
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patient the levels were clearly inadequate which, we believe, was largely due to poor 
compliance In fact this patient had already insufficient levels at the beginning of the 
treatment 
Correlation between nicotinamide side-effects and plasma levels Adequate assessment 
of the severity of side-effects was not possible in five cases three patients were taken out of 
the study because of very poor compliance with the treatment protocol, in one case it was 
decided to stop at day 4 because of pre-existing renal disturbances, and in one case reporting 
of side-effects was very inconsistent and unreliable and therefore not interpretable Thus, 35 
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Fig. 4. Nicotinamide plasma concentrations at the time of irradiation in seven patients 
Data obtained before dose reduction (first week), on 3 consecutive days directly 
after dose reduction, and during the last week of treatment Different symbols 
represent different patients (open circle patient with assumed poor compliance, 
closed circle patient discontinued nicotinamide intake) Dashed horizontal line 
indicates 700 nmol/ml level 
- 102-
Nicotinamide: pharmacokinetics, tolerance, compliance 
patients were évaluable for this analysis of which 16 patients experienced side-effects that 
were considered as severe. We investigated if the pharmacokinetic parameters could predict 
for nicotinamide toxicity by discriminant analysis. The following parameters were included: 
absolute daily dose, Cmax, area under the curve (AUC) derived from the first day profile, 
Cres, the mean of the plasma concentrations measured at the time of irradiation during the 
first week (Cmean), and whether or not accumulation occurred. There was no correlation 
between side-effects and absolute daily dose or Cres or AUC. High С
т а х
 (p = 0.03) and 
high C
m e a n
 (f = 0.008) were correlated with the occurrence of severe side-effects. There 
was a positive correlation between drug accumulation and severe side-effects but this did not 
reach statistical significance (p = 0.10). Eight of the 11 patients who showed drug 
accumulation had severe side-effects as compared to seven of the 23 patients in whom there 
was no indication of accumulation. The most powerful single predictor for severe 
nicotinamide toxicity was C
m e a n
 (Fig. 5). 
Discussion 
Tolerance: Gastrointestinal symptoms, flushing, dizziness, sweating, fatigue, and 
headache were already recognized as side-effects of nicotinamide [5, 8, 9, 20]. In a 
previous report we associated renal failure with nicotinamide intake as a relatively infrequent 
event but one that can have serious consequences [ 11 ]. In our total experience this occurred 
in three of 61 patients that were treated with nicotinamide. All three had received 
nephrotoxic medication previously (cisplatin) or concomitantly (ACE-inhibitor, 
carbasalatcalcium). Consequently we withheld nicotinamide in patients with pre-existing 
renal dysfunction and it was not administered concomitantly with nephrotoxic medication. 
Since then we have treated 41 other patients and no renal toxicity has been observed. One 
patient had a gastric bleeding. He also used carbasalatcalcium for analgesia which is a 
salicylate and known to cause gastric irritation which may have been enhanced by 
nicotinamide. One patient reported emotional lability and depressive moods. This was also 
noted in another patient treated previously. It remains unclear whether this relates to 
nicotinamide use. 
The most frequent adverse effect is nausea with or without vomiting. With prolonged 
daily administration it occurred in 65% of the patients and was often unresponsive to anti­
emetics confirming the findings from our previous study [11]. In 14 patients drug intake 
was either discontinued or the dose was reduced because these symptoms were severe and 
we did not allow these side-effects to significantly interfere with nutritional intake as this 
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was already impaired in most of our patients We observed a significant correlation between 
side-effects and some pharmacokinetic parameters In particular high plasma concentrations 
over subsequent days are associated with severe side-effects whereas absolute daily dose 
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Fig. 5. Mean of nicotinamide plasma concentrations measured at the time of irradiation 
during the first week of treatment Open symbols represent mean per patient (35 
patient·,) Patients are divided in two groups by severity of nicotinamide side-
effect1, (no-moderate versus severe) Closed symbols indicate mean values of the 
two groups with standard deviations 
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was not This indicates that, apart from direct topical irritation of the gastrointestinal 
mucosa, there is probably also a systemic effect Thus, alternative routes of drug 
administration may not circumvent the problem of nausea 
Severe clinical effects were reported with daily doses higher than 6 g or 80 mg/kg 
administered over a few subsequent days [4, 9] This was associated with high residual 24-
h plasma levels and significant drug accumulation It was suggested that accumulation can 
become of a particular concern when residual levels are higher than 300 nmol/ml [9] With 
the 80 mg/kg dose we observed relatively low residual values after the first drug intake 
(mean 66 nmol/ml) which did not predict for accumulation or side-effects 
Cmax ana" Tmax The nicotinamide plasma profiles obtained on the first treatment day 
show that, with a dose of 80 mg/kg, adequate (> 700 nmol/ml) levels could be obtained in 
all patients Large inter-patient variations in Cmax were seen however We used a liquid 
formulation which, on average, produced higher peak levels than tablets which were used in 
other studies [9, 19] and also shorter Tmax with a mean of 0 83 h (SD ± 0 73) as compared 
to 2 1 h (SD ± 1 3) with tablets [9] Apparently the drug is more rapidly absorbed when 
administered as a liquid formulation resulting in higher Cmax Initially, irradiations were 
given 1 5 h after drug intake but when an interim-analysis showed this short Tm a x , the 
interval was reduced to 1 h Eighty-three per cent (33/40) of the patients had Tmax < 1 h and 
the inter-patient variability was less than with tablets which can be of advantage for the 
timing of irradiations It has been suggested that absorption is also more rapid with higher 
peak concentrations when the drug is taken on an empty stomach [8, 9] Our patients were 
allowed to take a light meal at least 1 h before drug intake We found it not advisable for 
them to skip or postpone meals as most have impaired nutritional intake because of the 
location of the tumor and, as treatment progresses, because of radiation mucositis 
Compliance On the first 2 treatment days, when patients were hospitalized and 
nicotinamide was ingested in the presence of the nurse who was to obtain the plasma 
sample, nicotinamide levels at the time of irradiation were nearly always adequate With 
progression of treatment there was an increasing proportion of values below 700 nmol/ml 
with some being very low or even zero During the last week of the treatment nine of the 19 
patients who continued nicotinamide intake until the end of the treatment and without a dose 
reduction had repeatedly low values at the time of irradiation In some but not all cases this 
could be explained because the patient vomited shortly after nicotinamide intake. 
Alternatively, repeated administration of nicotinamide might possibly activate metabolic 
pathways resulting in a more rapid elimination of the drug However, full kinetic profiles 
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obtained in patients administered the same dose of nicotinamide daily, albeit over 12 days, 
showed no indication of this [9] Furthermore, together with nicotinamide concentrations, 
we measured the plasma levels of the three major metabolites of nicotinamide (1-methyl 
nicotinamide, nicotinamide N-oxide, and 2-pyndones) in our patients at the start of 
treatment and 5-7 weeks later (data not shown) The metabolite levels gave no indication of 
a faster elimination of the drug with time, ι e low levels of nicotinamide correspond with 
low levels of metabolites We must therefore assume a decreased compliance, ι e patients 
were not always taking the dose of nicotinamide they were supposed to This may well be 
caused by the experience of side-effects and the bad taste which is a disadvantage of the 
liquid formulation An additional argument is the often weak psychosocial status of head 
and neck cancer patients with inadequate self-care including poor drug compliance Other 
patient categories may do better in this respect 
Dose reduction The high mean plasma concentrations shown in Fig 5 suggest that a 
moderate dose reduction for those patients with severe adverse effects might still produce 
adequate plasma levels All but one had mean plasma levels greater than 900 nmol/ml at the 
time of irradiations It was shown that peak plasma levels are linearly dependent on the 
administered drug dose [8, 18, 19] If levels of at least 900 nmol/ml can be obtained with 
80 mg/kg, the expected minimum level after a 25% reduction of dose would be around 
700 nmol/ml or slightly lower We introduced a dose reduction to 60 mg/kg for patients 
who experienced severe nausea and/or intractable vomiting Tolerance improved after this 
moderate reduction of dose in six of seven patients and they were able to continue 
nicotinamide intake until the end of the treatment In five patients indeed plasma 
concentrations of about 75% of the initial values were obtained on some days but in only 
two patients this could be reproduced daily This is probably not attributable to the reduced 
drug dose only but also to a reduced compliance as was argued above Possibly, when the 
lower dose is administered from the start of treatment, better tolerance may also lead to 
improved compliance 
In rodent tumors, nicotinamide plasma levels between 700-1000 nmol/ml achieve 
significant increases in radiosensitization over that of carbogen alone [14] In this current 
study we have demonstrated that these levels can be achieved in man with oral doses of 
80 mg/kg but it is not always possible to reproduce such levels daily during a fractionated 
radiation treatment Lower doses may improve tolerance and compliance but the question 
arises whether such doses can produce drug levels sufficient for significant 
radiosensitization Further studies in experimental tumors are needed to determine the lower 
threshold dose for radiosensitization by nicotinamide It may also be helpful to obtain a 
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pharmacokinetic profile from each patient over the first 2 h after nicotinamide intake prior to 
the start of treatment for optimal timing such that patients are irradiated as close to their 
individual Tmax as possible. It has been shown that, with repeated drug administrations, the 
intra-patient variations of Tmax are small [9]. 
Conclusions: A nicotinamide dose of 80 mg/kg administered as a liquid formulation can 
produce peak plasma concentrations above the 700 nmol/ml level in all patients. Equivalent 
levels have been shown to be sufficient for radiosensitization in mice. However, due to 
adverse effects and loss of compliance, these concentrations could not be reproduced during 
the full course of the 5- to 7-week treatment in a significant portion of the subjects. High 
plasma concentrations over subsequent days are associated with severe side-effects and a 
25% dose reduction can improve tolerance. The question remains whether drug 
concentrations obtained after such dose reduction are still effective. Timing of irradiations 
may become more critical with the lower dose and further studies are needed to assess the 
threshold dose for radiosensitization by nicotinamide. 
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Abstract 
Tumor hypoxia and tumor cell repopulation are known factors determining radiation 
response Accelerated radiotherapy as a method to counteract cellular repopulation was 
combined with carbogen (95% O2 + 5% CO2) breathing and oral administration of 
nicotinamide as a means to improve tumor perfusion and oxygenation The feasibility, 
toxicity and clinical effectiveness of this approach as voice preserving treatment for 
carcinoma of the larynx was assessed in a prospective study 
Sixty-two patients with stage Ш-Г laryngeal carcinoma were treated with a schedule of 
accelerated radiotherapy Total radiation dose to the primary tumor was 64 Gy and that to 
the metastatic nodes was 68 Gy delivered in fractions of 2 Gy over 35-37 days 
Radiotherapy was combined with carbogen breathing in the initial 11 patients and with both 
carbogen and nicotinamide administration in the subsequent 51 patients 
After a median follow-up of 24 months, the actuarial local control rate at 2 years was 
92% This is higher than any previous report in the literature for this category of patients 
Five patients had a local tumor recurrence and underwent laryngectomy There was one 
regional recurrence Including salvage surgery the loco-regional control rate was 100% 
Four patients developed distant metastases and died The actuarial overall survival rate at 2 
years was 85% Toxicity was increased relative to conventional radiotherapy but was 
considered as acceptable One patient underwent laryngectomy for radiation-induced 
cartilage necrosis 
These preliminary results indicate that advanced laryngeal cancer can be controlled in a 
high proportion of patients when treated with accelerated radiotherapy combined with 
carbogen and nicotinamide This approach offers excellent possibilities for larynx 
preservation 
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Introduction 
It is a common clinical experience that some malignant tumors are highly curable by 
radiotherapy while others are not Major biological factors determining the radiation 
response of tumors include intrinsic radiosensitivity and DNA repair capacity, proliferative 
activity of clonogenic tumor cells and the tumor oxygenation status The radiosensitivity of 
squamous cell carcinomas is intermediate relative to tumors of other histology [33] Cellular 
repopulation and hypoxia have been shown to significantly influence radiotherapy outcome 
in this tumor type 
It has been observed from clinical data [46] and confirmed by studies with experimental 
tumors [23, 35] that the local tumor control probability decreases as the overall treatment 
time increases with a constant radiation dose, particularly in squamous cell carcinomas This 
is explained by an increase in the effective net production of tumor cells during the course of 
radiation treatment To counteract this repopulation of tumor clonogens, the overall 
treatment time can be reduced by giving the same total radiation dose with multiple fractions 
per day This strategy is called accelerated radiotherapy There is now evidence from 
randomized clinical trials that with accelerated radiotherapy, local tumor control can indeed 
be improved in patients with head and neck and bronchus carcinomas [1, 12, 30, 38] 
Tumor cell hypoxia is another well recognized cause for radiation resistance The 
response of cells to ionizing radiation is strongly dependent upon the availability of oxygen 
Two types of tumor hypoxia have been described Chronic or diffusion-limited hypoxia 
occurs at the edge of necrotic areas at a relatively constant distance from blood vessels, the 
diffusion distance of oxygen in tissue [42] Acute or transient hypoxia results from local and 
temporary fluctuations in tumor blood perfusion [3] Hypoxia appears to be present in the 
majority of rodent solid tumors and in xenografted human tumors [26, 34, 43] There is 
also substantial evidence for hypoxia in human tumors in situ [5] Tumor oxygenation status 
predicts the prognosis of patients receiving radiotherapy for carcinomas of the uterine cervix 
and the head and neck [8, 11, 28] A meta-analysis of 72 randomized clinical trials 
comparing radiotherapy alone or combined with a treatment to modify tumor hypoxia 
showed improvement of loco-regional control and survival following manipulation of tumor 
hypoxia [31] When analyzed according to site, this improvement was mainly in head and 
neck tumois 
New approaches in oxygenation modification with radiotherapy aim to simultaneously 
reduce acute and chronic hypoxia The amide derivative of vitamin B3, nicotinamide, can 
reduce the intermittent closure of blood vessels and consequently decrease acute hypoxia [4, 
13] Carbogen (95% oxygen and 5% carbon dioxide) breathing can increase the oxygen 
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partial pressure in tissues and reduce chronic hypoxia in patients with head and neck tumors 
[24] Many radiosensitizers have shown great promise when used with large single radiation 
doses, but the benefit has diminished in fractionation studies By contrast, studies in rodent 
tumors demonstrated significant sensitization when accelerated fractionated radiotherapy 
was administered together with a combination of carbogen and nicotinamide (ARCON) [35, 
36] An enhancement ratio of 1 9 was obtained with doses close to those used clinically, 
meaning that to obtain the same tumor control rate as with conventional radiotherapy without 
sensitizers, a 1 9 times lower radiation dose was needed with the ARCON treatment 
The aim of this study was to assess the feasibility, toxicity and clinical effectiveness of 
accelerated radiotherapy with carbogen and nicotinamide as an organ-preserving treatment 
for carcinoma of the larynx 
Patients and methods 
Design of the study The toxicity and clinical effectiveness of carbogen and 
nicotinamide added to a schedule of accelerated radiotherapy was investigated in this study 
The radiotherapy schedule was tested previously in patients with laryngeal carcinoma and 
considered tolerable [19] The first 11 patients in this study were treated with the accelerated 
schedule in combination with carbogen alone When this was shown to be feasible and 
without unacceptable early toxicity, the next 51 patients were treated with accelerated 
radiotherapy and both carbogen and nicotinamide 
Patients Patients referred to our center from November 1992 with previously untreated 
stage III and IV carcinoma of the larynx (1992 UICC classification system [16]) were 
considered for the study Inclusion criteria were an age over 18 years, a WHO performance 
status of 0-2, no severe heart or lung diseases, no severe liver or kidney function 
impairments, no severe stridor, no distant metastases and no concurrent treatment for other 
malignancies Twelve patients were ineligible according to these criteria Five patients were 
eligible but refused to participate Sixty-two patients were entered between November 1992 
and January 1997 
The mean age of the patients was 62 years (range 39-83 years) There were 47 men and 
15 women All patients had histologically confirmed squamous cell carcinomas Fourteen 
patients had glottic and 48 patients had supraglottic tumors Diagnostic work-up included 
examination under anesthesia with biopsy, CT- or MR-scanning and chest X-ray in all 
patients If an examination under anesthesia had already been performed by the referring 
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otolaryngologist, this was repeated in our center Ultrasound examination of the neck with 
fine needle cytology of suspect lymph nodes was performed in 55 of the 62 patients. All 
patients were discussed in a multi-disciplinary conference for tumor classification and 
treatment recommendation. Classification of the tumors is given m Table 1. According to the 
standard institutional protocol, patients with primary tumors classified as T4 are 
recommended to undergo laryngectomy Patients with T4 tumors included in this study 
either refused surgery or were considered to be poor candidates for laryngectomy 
This work was approved by the local ethics committee and written informed consent 
was obtained from all patients. 
Table 1. TNM-classificatwn of tumors. * 
No N1 N2b N 2 c Tota l 
T i 
T 2 
T 3 
T 4 
Tota l 
-
-
22 
8 
30 
-
6 
12 
1 
19 
'According to UICC 1992 [16] 
Radiotherapy Irradiations were given on a linear accelerator and patients were 
immobilized in custom-made casts. The primary tumor and bilateral neck nodes were 
irradiated through lateral opposed 4 or 6 MV photon beams. After 30-40 Gy the spinal cord 
was shielded and the posterior cervical neck nodes were treated with lateral appositional 
electron beams. The supraclavicular nodes were treated with an anterior photon field The 
boost dose was delivered through reduced lateral or oblique opposed portals, combined 
when necessary, with an electron beam to boost nodal areas overlying the spinal cord The 
initial treatment volume including the primary tumor, metastatic nodes and macroscopically 
uninvolved nodal areas ïeceived 44 Gy Subsequently, a boost of 20 Gy was given to the 
primary tumor and 24 Gy was given to metastatic nodes to a total dose of 64 and 68 Gy, 
respectively. The spinal cord dose did not exceed 40 Gy The dose per fraction was 2 Gy 
and treatments were given daily, five times per week, except during the last week and a half 
when treatments were given twice daily with an interval between fractions of at least 6 h 
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The total treatment time was 35-37 days The dose specification was according to Report 29 
oftheICRU[15] 
Carbogen breathing A scuba-diving breathing regulator (Scubapro, Brussels, 
Belgium) was used for carbogen delivery This system transports the gas from the reservoir 
to the patient by way of a two-step pressure reduction The first stage is attached to the 
reservoir and reduces pressure to 9 atmos (912 kPa) An intermediate pressure hose leads 
the gas to the second stage which further reduces pressure to 1 atmos (101 kPa) The 
second stage of the breathing regulator is connected to a disposable anesthetic face mask 
which is incorporated in the immobilizing cast Details of this breathing system have been 
described earlier [20] Carbogen breathing commenced 4 mm before irradiation and 
continued throughout 
Nicotinamide Nicotinamide (Pharmachemie, Haarlem, The Netherlands) was 
dissolved in fruit juice and administered orally 1 5 h before irradiations On days when two 
fractions were given, only one dose of nicotinamide was given before the first treatment 
Initially the daily dose was 6 g Based on subsequent pharmacokinetic data [14, 18], this 
was changed to a weight-adjusted dose of 80 mg/kg with a maximum of 6 g from April 
1994 and the interval between intake and irradiations was leduced to 1 h from November 
1995 Also from November 1995, a dose reduction to 60 mg/kg was introduced for those 
patients who experienced severe side-effects 
Monitoring during treatment and follow-up Assessment of side-effects and tumor 
response was done weekly during the treatment and thereafter until side-effects started to 
subside Patients were then seen once every 2 or 3 weeks until healing of skin and mucosa 
was complete At these visits they were asked if any adverse events had occurred and they 
weie specifically questioned about dysphagia, food intake, nausea and/or vomiting 
Physical examination included registration of body weight and assessment of mucosal and 
skin reactions and tumor response Thereafter, evaluations were performed once every 2 
months during the first year after treatment, every 3 months in the second year, every 4 
months in the third year and every 6 months from the fourth year on Follow-up visits 
included documentation of any relevant complaints, indirect laryngoscopy and/or 
laryngoscopy by flexible fiberoptic scope and palpation of the neck When a local recurrence 
was suspected, examination under anesthesia was performed and suspect abnormalities 
weie biopsied Chest X-rays were done once every 6 months during the first 2 years of 
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follow-up and once every year thereafter. Thyroid function was monitored before and after 
treatment. 
Statistical analysis Cumulative control and survival rates with standard errors (SE) 
were calculated from the date of pathologic diagnosis using the Kaplan-Meier method [21] 
This was done on a Macintosh computer with the Statistica 4 0 software package 
Results 
Compliance and acute morbidity Ten (16%) of the 62 patients were unable to breathe 
carbogen during the entire treatment period because of discomfort with the breathing 
procedure. Eight of these patients were unable to cope with the procedure from the 
beginning The other two patients discontinued carbogen breathing after 2 and 3 weeks, 
respectively. Apart from this, carbogen breathing produced no particular side-effects. 
Any side-effects that were felt to be related or possibly related to nicotinamide intake are 
listed in Table 2. The most common side-effects were nausea and vomiting, reported by 69 
and 39% of the patients, respectively. Of the 51 patients taking nicotinamide, 17 (33%) 
discontinued drug intake because of side-effects and nine (18%) had a dose reduction to 
60 mg/kg per day, after which they were able to continue nicotinamide intake until the 
completion of the treatment. 
Table 2. Side-effects attributed to nicotinamide in 51 patients 
Side-effect 
nausea 
vomiting 
flushing 
dizziness 
epigastric pain 
gastrointestinal bleeding 
headache 
sweating 
fatigue 
emotional disturbances 
No. of patients 
35 (69%) 
20 (39%) 
2 
2 
2 
1 
2 
1 
1 
1 
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All patients completed the treatment within the planned time of 35-37 days All but two 
patients developed confluent mucositis, ι e formation of a confluent fibrinous 
pseudomembrane The peak incidence was in the 2 weeks following the end of the treatment 
and the median duration was 6 weeks (range 2-15 weeks) In all cases there was complete 
healing of the mucosa Due to the mucosal reactions and consequent dysphagia, 17 (27%) 
patients required temporary feeding by nasogastric tube or percutaneous gastrostomy 
Indications for tube feeding were a weight loss > 10% of the initial body weight or 
insufficient intake of liquids The median duration of tube feeding was 7 weeks (range 2-16 
weeks) Moist desquamation of the skin was observed in 38 (61%) patients with a median 
duration of 2 weeks (range 1-12 weeks) and complete healing in all patients 
Loco-regional control and survival The median follow-up at the time of analysis was 
24 months (range 8-50 months) and no patients have been lost to follow-up Evaluation at 6 
weeks after the treatment demonstrated a complete regression of the primary tumor and the 
nodal metastases in all cases, ι e a complete response rate of 100% Five patients 
experienced a local recurrence at 5, 8, 14, 18, and 31 months, respectively Two of these 
received carbogen only and the other three received both carbogen and nicotinamide, but of 
these, two discontinued nicotinamide after 8 and 25 days, respectively, because of side-
effects Actuarial local control rates were 92% (SE 3 9%) at 2 years and 87% (SE 6 0%) at 
3 years (Fig 1) There was one patient with a neck node recurrence at 13 months The five 
patients with local recurrence underwent total laryngectomy and the one patient with nodal 
ìecurrence underwent a neck dissection and re-irradiation All remained free of loco-regional 
disease Thus, including salvage surgery, the actuarial loco-regional control was 100% 
Four patients died of metastatic disease (three cases in the lung and one case in the liver) At 
the time of analysis all patients alive were free of disease The actuarial overall survival was 
85% (SE 5 5%) at 2 years and 77% (SE 7 2%) at 3 years (Fig 2) 
Late complications One patient developed laryngeal edema with persistent dysphagia 
and otalgia 3 months after the completion of treatment, suggestive of radiation-induced 
chondritis Repeated examinations under anesthesia showed an ulcerating lesion on the 
epiglottis without histopathologic evidence of recurrent carcinoma This patient underwent a 
total laryngectomy because of persistent seveie pain 9 months after the completion of 
radiotherapy Histologic examination of the surgical specimen showed chiome inflammation 
with necrosis and destruction of caitilage, there was no evidence of recurrent carcinoma 
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Three other patients had late episodes of similar symptoms and dysphagia necessitated 
tube feeding for 2-6 months after which these symptoms settled Temporary or permanent 
severe laryngeal edema not requiring any surgical intervention was observed in 11 patients 
One of the six patients who underwent laryngectomy developed a pharyngo-cutaneous 
fistula postoperatively 
Discussion 
In many institutions the standard treatment for T3 and T4 squamous cell carcinoma of 
the larynx is still total laryngectomy, with or without postoperative radiotherapy Loco-
regional control rates of 68-95% can be obtained with this approach [27, 47] The 
consequence of total laryngectomy is substantial functional loss, the most important of 
which is the loss of the natural voice The organ-preserving alternative is radiotherapy 
However, with conventional methods tumor control is obtained in only about 23-53% of 
patients depending on site, stage and selection criteria [2, 40, 44] Based on 
accomplishments of radiobiological research, new approaches in clinical radiotherapy have 
been developed to improve treatment outcome These include alternative fractionation 
schedules and methods to improve tumor oxygenation Table 3 summarizes the results of 
radiotherapy approaches for advanced laryngeal cancer which are further discussed below 
Two randomized clinical trials in head and neck cancer, comparing radiotherapy in 
hyperbaric oxygen and radiotherapy in air, demonstrated a significant improvement of local 
control with hyperbaric oxygen [9, 10] In the second study, 2-year control rates of 42% 
with air and 73% with hypeibanc oxygen were obtained for T3 and T4 laryngeal carcinomas 
[9] Delivery of radiation in hyperbaric oxygen is, however, a demanding technique and 
therefore the approach has not gained general acceptance 
The Radiation Therapy Oncology Group (RTOG) conducted a randomized study 
comparing radiotherapy alone and radiotherapy with carbogen breathing in patients with 
stage II-IV head and neck carcinomas [37] Overall local tumor control for all head and neck 
regions combined was 51 % with no difference between the two arms A greater control rate 
was observed in the carbogen arm for the larynx tumors but, due to the small numbers in 
this subgroup, no significance could be given to this observation This study was criticized 
because of possible improper timing of carbogen breathing relative to the delivery of 
radiotherapy In animal studies the maximum sensitizing effect of carbogen was observed 
after a preirradiation breathing time of 5 min with a decreased effect with longer times, 
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apparently due to physiological compensatory mechanisms [39] In the RTOG study 
preirradiation breathing times were generally longer 
Nitro-irmdazole compounds have been used as hypoxic cell sensitizers in combination 
with radiotherapy These drugs mimic the sensitizing effect of oxygen In a randomized 
study, it was demonstrated that radiotherapy with nimorazole (l-(N-ß-efhyl-morpholine)-5-
nitro-imidazole) improves loco-regional control in stage П-І supraglottic larynx carcinomas 
from 35 to 53% [29] 
Accelerated radiotherapy for head and neck cancer has been tested in four randomized 
studies which were recently completed [1, 6, 12, 30] Preliminary results from all four 
studies are consistent with the hypothesis that shortening of treatment time can improve 
tumor control The largest gain in loco-regional control (13%) was obtained in the EORTC 
study [12] However, this was accompanied by an increase of the complication rate 
requiring further modification of the fractionation schedule 
By lowering the dose per fraction and giving multiple fractions per day a higher 
radiation dose can be delivered to the tumor without increasing late morbidity This 
hyperfractionation exploits the difference in the fractionation sensitivity between rapidly and 
slowly renewing tissues to improve tumor control probability Various schedules of 
hyperfractionation have been tested By reducing the dose per fraction to 1 1-1 2 Gy and 
delivering two treatments per day the total dose can be escalated to 74-77 Gy This strategy 
yields a local control rate of 68% for T3 supraglottic and glottic carcinomas [25, 32] At the 
MD Anderson Cancer Center, control rates of 77-84% (1 1 and 1 2 Gy per fraction, 
respectively) were obtained for supraglottic carcinomas [7] In the latter study, about two-
thirds of the tumors were T2 and there were almost no T4 lesions, thus, overall, disease was 
less advanced compared to the current study 
Wang et al have combined elements of both accelerated and hyperfractionated 
radiotherapy [45] With a moderate reduction of dose per fraction to 1 6 Gy and total doses 
of 64-67 Gy given in 6 weeks, they reported a 3-year actuarial control rate of 63% for T3 
and T4 larynx carcinomas 
Another modality that has been investigated foi its value in larynx pieservation is 
chemotherapy The Department of Veterans Affairs Cooperative Studies Program 
coordinated a prospective randomized study in patients with stage III-IV laryngeal 
carcinoma [41] This trial compared a standard treatment of surgical resection followed by 
radiotherapy and an experimental treatment in which neoadjuvant chemotheiapy (cisplatin 
and 5-fluorouracil) was followed by radiotherapy for responders and surgery for non-
responders The distribution of patients by T-stage was very similar to the current study 
For the 166 patients assigned to the chemotheiapy arm, the rate of larynx preservation after 
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2 years was 66% Another phase III trial compared continuous course radiotherapy with 
split course radiotherapy plus concurrent chemotherapy (mitomycin С and 5-fluorouracil) 
for advanced laryngeal and hypopharyngeal carcinoma [22] The actuarial 2-year local 
relapse free rate for the larynx carcinomas was 45% in both arms (N = 129) 
In the current study we combined accelerated radiotherapy with carbogen to reduce 
chronic diffusion-limited tumor hypoxia and with nicotinamide to reduce acute hypoxia 
Carbogen was preferred over pure oxygen because of the respiratory stimulation and a 
possible advantageous effect on microregional blood flow This approach yields a 2-year 
local control rate of 92% for patients with stage III-IV laryngeal carcinoma This is higher 
than any previous report in the literature for this category of patients 
The compliance rate for carbogen breathing was 84% The most important side-effects 
of nicotinamide were nausea and vomiting which caused 33% of patients to discontinue 
drug intake This moderate compliance to nicotinamide calls for measuies to improve drug 
tolerance Anti-emetic treatment can be intensified and the drug dose can possibly be 
reduced without losing the sensitizing effect Nicotinamide tolerance and pharmacokinetics 
have been discussed in detail in previous papers [17, 18] Studies in rodent tumors 
demonstrated a significant improvement of the sensitizing effect of the combination of 
carbogen and nicotinamide relative to carbogen alone [35, 36] Of the five patients in this 
study who developed a local recurrence, two were m the group without nicotinamide and 
two discontinued nicotinamide intake because of side-effects This study, however, was not 
designed to assess the relative effectiveness of each of the individual components of 
ARCON A large-scale clinical study would be needed to address this question 
Accelerated radiotherapy elevates radiation reactions not only in tumors but also in 
rapidly repopulating normal tissues, in particular the mucosal lining [19] There is some 
additional enhancement from carbogen and nicotinamide [17] With the schedule used in this 
study, almost all patients developed confluent mucositis and 27% required temporary tube 
feeding However, there was complete healing of the mucosa in all patients and we consider 
these side-effects as acceptable 
One of our patients developed necrosis of the laryngeal cartilage requiring 
laryngectomy The initial study with hyperbaric oxygen by Henk et al demonstrated a 
decrease in radiation tolerance of the laryngeal cartilage [10] A 10% reduction of the total 
radiation dose in the subsequent study reduced the laryngeal complications to a level seen 
with treatment in air [9] Since a similar effect might have been expected from normobanc 
carbogen with nicotinamide in the current study, we limited the total dose to the larynx to 
64 Gy which is almost a 10% reduction relative to our conventional dose of 70 Gy The 
good results despite this reduced radiation dose strongly support the concept of an increased 
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tumor effectiveness of these biologically-based treatment modifications. A phase III trial is 
needed to assess the magnitude of the therapeutic gain. 
These preliminary results indicate that in advanced laryngeal cancer, high tumor control 
rates can be obtained when accelerated radiotherapy is combined with carbogen and 
nicotinamide. This approach offers excellent possibilities for larynx preservation. 
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Summary 
Chapter 1 is an introduction and briefly reviews the most important mechanisms of 
radiation resistance. The focus is on squamous cell carcinomas of the head and neck. 
Radiotherapy is a principal treatment modality for this category of malignancies and of 
special interest because of its organ preserving potential. Of particular importance in head 
and neck carcinomas are cellular repopulation and hypoxia. This has been demonstrated in 
experimental and human tumors. Novel approaches in radiotherapy have been developed to 
overcome these resistance mechanisms. Several were tested in randomized trials and proved 
to be effective. Notwithstanding the successfulness of some of these new treatment 
approaches, there is room for further improvement. It is suggested that further work should 
concentrate on two strategies: 1) Identification of tumors or classes of tumors that are most 
suitable for either of the new treatments and 2) Simultaneously counteracting different 
radioresistance mechanisms by combination of treatment modifications. The latter was the 
aim of this work and it is outlined how accelerated radiotherapy together with methods for 
hypoxic modification was introduced in the clinic. This treatment is called "ARCON: 
Accelerated Radiotherapy with CarbOgen and Nicotinamide". 
Chapter 2 is a study on the acute and late toxicity of a newly developed schedule for 
accelerated radiotherapy. A moderate reduction of overall treatment time to 5-5.5 weeks was 
accomplished by giving two radiation fractions a day during the last part of the treatment. 
The total dose and dose per fraction were unchanged relative to conventional treatment. The 
feasibility and toxicity of this schedule were assessed in patients with laryngeal cancer. 
Early mucosal reactions and, to a lesser extent, also skin reactions were enhanced compared 
to conventional treatment. There was an indication of a small increase in the incidence of late 
effects, i.e. laryngeal edema, as well. It is concluded that the toxicity of this schedule 
remains within the limits of tolerance. Further shortening of overall treatment time without 
reduction of total dose is not recommended because this might lead to unacceptable acute 
mucosal reactions. 
The experimental and clinical data on radiation mucositis are reviewed in chapter 3 
with the aim to assess whether indeed the upper aerodigestive tract mucosa is limiting to 
treatment intensification by altered fractionation. It is concluded that the maximum 
achievable gain in treatment time is 2 weeks, relative to a conventional treatment of 7 weeks, 
with the mucosa being the limiting tissue. Any further acceleration requires a reduction of 
dose. This can be disadvantageous, in particular for tumors with relatively low intrinsic 
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radiosensitivity It is also concluded that manipulations with the temporal distribution of 
dose and fraction dose, and optimization of intervals between fractions may improve 
tolerance but are unlikely to allow a significant further intensification of the existing 
accelerated schedules Dose escalation by hyperfractionation seems to be limited by late 
sequelae more than by acute mucosal reactions Finally, it is briefly discussed which agents 
are available to prevent or ameliorate radiation mucositis Unfoitunately, none of these 
agents appears to be sufficiently effective to recommend its application as standard practice 
The effect of carbogen (95% O2 + 5% CO2) breathing, one of the components of 
ARCON, is a rise of the oxygen partial pressure in the blood and tissues and a consequent 
reduction of diffusion-limited hypoxia in tumors Patients with head and neck tumors may 
have difficulties with gas breathing, in particular when the tumoi is located in the uppei 
airway In addition, for these patients a custom-made cast is needed for immobilization 
during irradiations Chapter 4 describes a breathing system that was developed to be 
combined with the fixating cast and which would ensuie good compliance This system is 
based on professional diving equipment and a disposable anesthetic face mask which is 
incorporated in the fixating cast Theie was full compliance with this method of carbogen 
breathing in 84% of 62 patients with laryngeal cancer (chapter 7) 
Chapter 5 reports on the feasibility and toxicity of ladiotheiapy to the head and neck 
area when combined with carbogen and nicotinamide Nicotinamide, the third component of 
ARCON can modify tiansient hypoxia by opening temporarily closed tumor blood vessels, 
thereby increasing blood perfusion Carbogen and nicotinamide weie added in consecutive 
steps to schedules of conventional and accelerated radiotherapy Thirty-four patients with far 
advanced tumors of the oral cavity and oropharynx received conventional radiotheiapy with 
carbogen (N = 16) or with carbogen and nicotinamide (N = 18) Forty patients with 
laryngeal and hypopharyngeal carcinomas were treated with accelerated radiotherapy 
combined with carbogen (N = 16) or with carbogen and nicotinamide (N = 24) Some 
enhancement of skin leactions was observed with nicotinamide but generally the skin healed 
ïapidly and the reactions weie well within the limits of tolerance With the acceleiated 
schedule alone almost all patients developed confluent mucositis (chapter 2) Additional 
enhancement by carbogen and nicotinamide was expressed as delayed healing of the 
mucosal lining This toxicity was manageable and within acceptable limits A fuither 
intensification of the tieatment is however not advocated because this might then lead to 
non-healing mucosal damage in some patients Fiequent side-efrects of nicotinamide weie 
nausea (60%) and vomiting (36%) Seveie renal dysfunction was associated with 
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nicotinamide intake in three patients It is recommended that nicotinamide should not be 
given concomitantly with nephrotoxic medication or to patients with impaired renal function 
The pharmacokinetics, tolerance, and compliance to nicotinamide were further 
investigated in chapter 6 In 40 patients nicotinamide plasma levels were determined A 
full pharmacokinetic profile was obtained on the first day of the treatment followed by daily 
samples at the time of irradiation during the first and last weeks In all patients peak 
concentrations adequate for radiosensitization could be obtained The plasma levels 
decreased however towards the end of the treatment which was partly attributed to reduced 
compliance There appeared to be an association between severe side-effects and high 
plasma concentrations over subsequent days There was an indication that tolerance could be 
improved by a 25% reduction of the drug dose Whether adequate plasma levels can be 
obtained with this reduced dose is the subject of ongoing investigations 
In chapter 7 the effectiveness of ARCON in terms of tumor response was assessed in 
62 patients with stage ІП-І laryngeal carcinomas Accelerated radiotherapy was given with 
carbogen in the initial 11 patients and with both carbogen and nicotinamide in the 
subsequent 51 patients With a median follow-up of 24 months, the actuarial local control 
rate at 2 years was 92% There was one regional recurrence Including salvage surgery the 
ultimate loco-regional control rate was 100% The actuarial overall survival rate was 85% at 
2 years One patient underwent laryngectomy for radiation-induced cartilage necrosis The 
literature on radiotherapy for advanced laryngeal cancer is briefly reviewed Control rates 
with conventional methods are in the range of 23-53% This can be improved by 
hyperfractionation and use of hypoxic modifiers to 53-84% depending on site, stage, and 
selection criteria The control rate in the current study is higher than any previous report in 
the literature and must be confirmed, preferably in a phase III trial The organ preserving 
potential of ARCON can offer a significant improvement of the quality of life of patients 
with advanced laryngeal cancer 
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Samenvatting 
Hoofdstuk 1 is een introductie en geeft een beknopt overzicht van de belangrijkste 
mechanismen die de stralingsgevoeligheid van een tumor bepalen Het accent ligt hjerbij op 
de plaveiselcelcarcinomen van het hoofd-, halsgebied Radiotherapie is een van de 
belangrijkste behandelingsmodahteiten voor deze categorie van maligniteiten en met name 
interessant vanwege het orgaansparende karakter Bij carcinomen van het hoofd-, 
halsgebied spelen met name tumorcel repopulatie en hypoxie een belangrijke rol Dit is 
aangetoond in zowel experimentele als humane tumoren Nieuwe benaderingen in de 
radiotherapie zijn er op gericht om deze resistentie mechanismen zoveel mogelijk te 
compenseren De effectiviteit van enkele van dergelijke nieuwe behandelingen is bewezen in 
gerandomiseerde studies Desalniettemin is er ruimte voor verdere verbeteringen Het 
voorstel is daarom om verder onderzoek te concentreren op een tweetal strategieën 
1) Identificatie van tumoren of categorieën van tumoren die het meest geschikt zijn voor de 
diverse nieuwe behandelingen en 2) Gebruik maken van een combinatie van verschillende 
modificaties van de behandeling om zodoende te compenseren voor meerdere resistentie 
mechanismen tegelijk Dit laatste was het doel van dit onderzoek In dit proefschrift wordt 
beschreven hoe versneld gefractioneerde bestraling tezamen met methoden voor modificatie 
van hypoxie voor klinische toepassing werd geïntroduceerd Deze behandeling wordt 
"ARCON" genoemd "Accelerated Radiotherapy with CarbOgen and Nicotinamide" 
Hoofdstuk 2 beschrijft een studie naar de acute en late toxiciteit van een nieuw 
ontwikkeld schema voor versneld gefractioneerde bestraling Door gedurende het laatste 
deel van de behandeling twee bestralingen per dag te geven werd de totale behandehngsduur 
verkort tot 5-5,5 weken De totale dosis en dosis per fractie bleven onveranderd in 
vergelijking met het conventionele schema De uitvoerbaarheid en toxiciteit van dit schema 
werden onderzocht bij patiënten met een larynxcarcmoom De acute slijmvliesreacties en, in 
mindere mate, ook de huidreacties waren toegenomen in vergelijking met conventionele 
behandeling Er waren tevens aanwijzingen voor een geringe toename van de incidentie van 
late effecten, namelijk oedeem van de larynx De conclusie van deze studie is dat het 
betreffende schema voor versnelde fractionenng tolerabel is Nog verdei e verkorting van de 
behandehngsduur zonder reductie van de bestrahngsdosis wordt echter afgeraden omdat dit 
mogelijk kan leiden tot onacceptabele acute toxiciteit van het slijmvlies 
Een overzicht van de experimentele en klinische gegevens betreffende 
bestrahngsmucositis wordt gegeven in hoofdstuk 3 Doel hiervan is om te onderzoeken of 
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inderdaad de reactie van het slijmvlies van de mond- en keelholte beperkend is bij verdere 
intensivering van fractionenngsschema's Geconcludeerd wordt dat ten opzichte van een 
conventioneel schema van 7 weken de behandehngsduur met maximaal 2 weken verkort kan 
worden waarbij de slijmvhestoxiciteit de beperkende factor wordt. Wil men de 
behandehngsduur nog verder verkorten dan is ook een reductie van de totale 
bestralingsdosis nodig Dit kan nadelig zijn, met name bij tumoren met een relatief lage 
intrinsieke stralingsgevoehgheid Uit de gegevens wordt ook geconcludeerd dat de tolerantie 
wellicht verbeterd kan worden door optimalisatie van de verdeling van dosis in de tijd, van 
de dosis per fractie en van de tijdsintervallen tussen de fracties De verwachting is echter niet 
dat hierdoor een significante verdere verkorting van de behandehngsduur mogelijk wordt 
Verhogen van de dosis door hyperfractionenng lijkt meer beperkt te worden door de late 
effecten van bestraling dan door de acute slijmvhesreacties Besloten wordt met een korte 
bespreking van potentiële middelen die bestrahngsmucositis kunnen voorkomen of 
verminderen Helaas blijkt geen van deze middelen effectief genoeg om routinematige 
toepassing in de dagelijkse praktijk aan te bevelen 
Het ademen van carbogeen (95% O2 + 5% CO2), een van de componenten van 
ARCON, veroorzaakt een toename van de zuurstofspanning in bloed en weefsels en 
daarmee een afname van de zogenaamde "diffusie afhankelijke" hypoxie in tumoren 
Patienten met hoofd-, halstumoren kunnen moeite hebben met het ademen van het 
carbogeengas, met name wanneer de tumor in de bovenste luchtweg is gelokaliseerd 
Daarnaast wordt voor immobilisatie tijdens de bestralingen gebruik gemaakt van een 
individueel op maat gemaakt gezichtsmaskei Hoofdstuk 4 beschrijft een ademsystcem dat 
gecombineerd kan worden met het gezichtsmasker en dat tevens goed verdragen wordt en 
voldoende theiapietrouw verzekeit Dit systeem is gebaseerd op professionele 
duikappaiatuur en een anesthesiekapje dat ín het gezichtsmasker wordt gebouwd Het 
carbogeen ademen verliep geheel adequaat bij 84% van 62 patiënten met een 
larynxcarcinoom (hoofdstuk 7) 
Hoofdstuk 5 beschrijft een studie naar de uitvoerbaarheid en de toxiciteit van 
radiotherapie in het hoofd-, halsgebied wanneer dit gecombineerd wordt met carbogeen en 
nicotinamide Nicotinamide, de derde component van ARCON, kan de zogenaamde 
"tijdelijke" hypoxie doen verminderen door het heropenen van bloedvaten die tijdelijk 
gesloten zijn waardoor de bloeddoorstioming in de tumor verbetert Carbogeen en 
nicotinamide werden stapsgewijs toegevoegd aan zowel conventionele als versneld 
gefractioneerde bestialing Vierendeitig patiënten met een ver gevoiderde tumor van de 
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mondholte of orofarynx werden behandeld met conventionele radiotherapie gecombineerd 
met carbogeen (N = 16) of met carbogeen én nicotinamide (Ν = 18) Veertig patiënten met 
larynx- of hypofarynxcarcinomen werden behandeld met versnelde fractionenng in 
combinatie met carbogeen (N = 16) of met carbogeen én nicotinamide (Ν = 24) Er was 
enige toename van de huidreactie met nicotinamide maar in het algemeen hei stelde de huid 
snel en deze bijwerking werd goed verdragen Met het versnelde schema ontwikkelden 
vrijwel alle patiënten een confluente mucositis (hoofdstuk 2) Er was een veidere toename 
van de slijmvliesreactie door toevoeging van carbogeen en nicotinamide, hetgeen tot uiting 
kwam als een vertraagde genezing van het slijmvlies Deze bijwerking bleef binnen 
hanteerbare en acceptabele grenzen Een verdere intensivering van de behandeling wordt 
echter ontraden omdat dit dan wellicht kan leiden tot irreversibele schade van het slijmvlies 
bij een deel van de patiënten De meest voorkomende bijwerkingen van nicotinamide waren 
misselijkheid (60%) en braken (36%) Bij drie patiënten was er sprake van een ernstige 
niennsufficientie onder nicotinamide gebruik Aanbevolen woidt om nicotinamide niet 
gelijktijdig te geven met andere, nefrotoxische, medicatie en ook niet aan patiënten met een 
gecompromitteerde nierfunctie 
De farmacokinetische eigenschappen alsmede de tolerantie en de compliance voor 
nicotinamide werden verder onderzocht in hoofdstuk 6 Bij 40 patiënten werd de 
concentratie van nicotinamide in het plasma bepaald Op de eeiste dag van bestialing werd 
een volledig profiel van de plasmaconcentraties verkregen, gevolgd door dagelijkse 
bepalingen op het moment van bestraling tijdens de eeiste en laatste week van de 
behandeling Bij alle patiënten konden maximale plasmaconcentraties bereikt worden die 
voldoende hoog waren om een sensibiliserend effect te verkrijgen De plasmaconcentraties 
werden echter lager naarmate de bestralingsbehandehng vorderde Gedeeltelijk werd dit 
toegeschreven aan een afname van de theiapietrouw Er bleek een correlatie te bestaan 
tussen het optreden van ernstige bijwerkingen en hoge plasmaconcentraties op 
opeenvolgende dagen Er was een aanwijzing dat de tolerantie mogelijk veibeteid kan 
worden door een dosisreductie van 25% Of met deze gereduceerde dosis ook adequate 
plasmaconcentiaties kunnen woiden veikiegen is thans ondeiweip van ondeizoek 
Hoofdstuk 7 beschrijft een onderzoek naar het tumor-effect van ARCON bij 62 
patiënten met een stadium III of IV laiynxcarcinoom Versneld gefractioneeide bestialing 
werd gegeven in combinatie met caibogeen bij de eeiste 11 patiënten en in combinatie met 
zowel caibogeen als nicotinamide bij de volgende 51 patiënten De actuanele lokale contiole 
na 2 jaai was 92% bij een mediane follow-up van 24 maanden Er was eén patient met een 
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regionaal recidief De uiteindelijke loco-regionale controle na "salvage"-chirurgie was 
100% De actuariële overleving na 2 jaar was 85% Eén patient onderging een laryngectomy 
vanwege een door de bestraling geïnduceerde kraakbeennecrose In dit hoofdstuk wordt 
verder een beknopt overzicht gegeven van de resultaten van radiotherapie bij het gevorderde 
larynxcarcinoom Met conventionele methoden kan bij 23-53% van de patiënten tumor-
controle worden verkregen Met hyperfractionenng en methoden voor modificatie van 
hypoxie kan dit worden verbeterd tot 53-84% afhankelijk van lokalisatie en stadium van de 
tumor alsmede toegepaste selectiecriteria De lokale controle die in deze studie werd bereikt 
is hoger dan bij enig eerder gepubliceerd onderzoek Dit resultaat dient te worden bevestigd, 
bij voorkeur middels een gerandomiseerde fase III studie Het orgaansparend potentieel van 
ARCON kan een belangrijke verbetering van de kwaliteit van leven opleveren bij patiënten 
met een gevorderd larynxcarcinoom 
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Accelerated radiotherapy with 
carbogen and nicotinamide 
for carcinomas of the head and neck 
A study on feasibility, toxicity and tumor response 
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Nijmegen, 9 december 1998 
1. Rational and stepwise incorporation of well-established radiobiological 
principles in clinical trials definitely leads to important improvements in 
treatment outcome. The question is not if, but how to implement these 
principles in the daily practice of radiotherapy. 
This thesis. 
2. The additional costs of ARCON-treatment relative to conventional 
radiotherapy amount to 100 Dutch guilders per patient. When ARCON is 
compared with other experimental treatments including chemotherapy, 
immunotherapy and conformai radiotherapy, there seems to be an inverse 
relationship between the costs of these treatments and the therapeutic gain. 
3. For radiotherapy of head and neck tumors, relative to a conventional 
treatment of 7 weeks, the maximum achievable gain in treatment time is 2 
weeks with the mucosa being the limiting tissue. Any further acceleration 
requires a reduction of dose. 
This thesis. 
4. Every patient presenting with a larynx carcinoma should be considered for 
an organ preserving treatment. 
This thesis. 
5. Of all new treatment strategies for head and neck cancer, accelerated 
radiotherapy is currently the most successful in randomized clinical trials. 
A strong case can be made for the introduction of this approach as the 
standard treatment for certain patient categories. 
6. Limited machine capacity is an invalid argument for not using accelerated 
radiotherapy. 
This thesis. 
7. The distinction between acute and chronic hypoxia is a major 
simplification of a condition with continual temporal and spatial 
fluctuations of both oxygen delivery and oxygen consumption. 
"Radiotherapeutische behandeling" is een pleonasme. Het is beter om 
"radiotherapie" of "bestralingstherapie" te zeggen. 
Kwaliteitsbevordering is in de mode, ook binnen de gezondheidszorg. In 
hoeverre dit zal leiden tot een daadwerkelijk betere behandeling van de 
patiënt valt nog te bezien. 
De aanduiding "millenniumprobleem" is niet correct. Het probleem wordt 
immers veroorzaakt door een eeuwwisseling en dient daarom 
"centenniumprobleem" te heten. Het feit dat deze eeuwwisseling 
samenvalt met een millenniumwisseling is geen reden om het probleem 
buiten proporties op te blazen. 
Als het centenniumprobleem is opgelost zijn we de komende acht 
millennia uit de zorgen. 
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